

MEETING OF THE INTERNATIONAL PEMPHIGUS & PEMPHIGOID FOUNDATION



www.ippf2024-skg.gr

THESSALONIKI Greece **2024** August 29th – 31st
Hotel Makedonia Palace

ORGANISED BY



FINAL PROGRAM

Reaching patients through immunology innovation: Together we discover

A **global immunology** company developing medicines for people with **severe autoimmune diseases** through our best-in-class, **differentiated pipeline of immunology solutions**.



Innovation

Our Core Mission

We live to innovate - and do so at every step



Co-Creation

We Create Through Collaboration

We trust in the power of the team and know that together we are better



Empowerment

We Share in Our Joint Purpose

Our people are our most valuable asset



Excellence

We Have a Quality Culture

We want to do things right the first time and prioritize patient safety



Humility

The Heart of Our Organization

We want to handle successes and challenges gracefully and learn from both

Discover more at argenx.com





TABLE OF CONTENTS

COMMITTEES	4
WELCOME MESSAGE	5
ABOUT IPPF	6
FACULTY MEMBERS	8
PROGRAM AT-A-GLANCE	12
SCIENTIFIC PROGRAM	13
E-POSTERS	27
GENERAL INFORMATION	37
ACKNOWLEDGEMENTS	45
SPONSORS PROFILES	46
IPPF 2024 MOBILE APP	48



COMMITTEES

PLANNING (PROGRAM) COMMITTEE

Aikaterini Patsatsi
Marc Yale
Patrick Dunn

Dedee F. Murrell
Aimee Payne
Enno Schmidt

Victoria Werth
Jun Yamagami

SCIENTIFIC (ABSTRACT) COMMITTEE

Valeria Aoki
Frederic Caux
Donna Culton
Kosara Drenovska
Dipankar De
Janet Fairley

Barbara Horvath
Michael Hertl
Pascal Joly
Yen Loo Lim
Branka Marinović
Angelo Marzano

Daniel Mimouni
Meng Pan
Carlo Pincelli
Eli Sprecher
Soner Uzun
Snejina Vassileva

LOCAL ORGANIZING COMMITTEE

Aikaterini Patsatsi (Chair)

Elisabeth Lazaridou
Elena Sotiriou
Theodoros Sidiropoulos
Myrto - Georgia Trakatelli

Zoe Apalla
Anastasia Trigoni
Efstratios Vakirlis

Aimilios Lallas
Florentina Delli
Dimitra Kyritsi

HONORARY MEMBERS OF THE LOCAL ORGANIZING COMMITTEE

Fotios Chrysomallis

George Chaidemenos

Dimitrios Ioannides

Dimitrios Sotiriadis

THE GREEK BULLOUS DISEASES STUDY GROUP

Vasiliki Chasapi
George Gaitanis
Sofia Georgiou
Maria Gerochristou
Aikaterini Grafanaki
Agoritsa Gravani

Alexandros Katoulis
Marilina Konstantinou
Konstantinos Krasagakis
Elisabeth Lazaridou
Markos Papakonstantis
Aikaterini Patsatsi


Aggeliki Roussaki - Schulze
Theodoros Sidiropoulos
Elena Sotiriou
Effie Soura
Alexander Stratigos
Konstantinos Theodoropoulos

GREEK CENTER OF EXPERTISE ON AIBD - PAPAGEORGIOU GENERAL HOSPITAL - MULTIDISCIPLINARY TEAM

Dimitrios Andreadis
Maria Bantadaki
Maria - Eleni Besina
Maria Boziou
Anthi Chatzikyriakidou
Athina Daponte
Alexandra Demka
Alexandra Fleva
Anastasia Giannakou
Evaggelia Kalloniati
Sokratis Katafygiotis

Irena Katsanika
Iordanis Konstantinidis
Aikaterini Kyriakou
Parthena Kyriklidou
Alexandros Lambropoulos
Maria Lambropoulou
Fotini Lamprou
Elisabeth Lazaridou
Panagiota Lazidou
Maria Markopoulou
Parthena Meltzanidou

Valentina Oflidou
Alexandros Onoufriadis
Vasiliki Papadimitriou
Vasiliki Papadopoulou
Aikaterini Patsatsi
Maria Stavropoulou
Evaggelia Tsakiropoulou
Anastasia Tsitlakidou
Argyrios Tzamalīs
Glykeria Tzatzagou
Vasiliki Zioga



WELCOME MESSAGE

Dear colleagues and friends,

It is our great honor and pleasure to welcome you to the **International Pemphigus & Pemphigoid Foundation Meeting**, taking place in the captivating city of **Thessaloniki, Greece**, from **August 29 to 31, 2024**.

Most of the basic and clinical scientists in the field of autoimmune bullous diseases will get together in Thessaloniki in 2024.

Under the chosen theme “**“Pemphix, Πέμφιξ” from the Greek routes to the modern era of developments in clinical recognition, diagnostics and therapeutics**”, we will come together to share knowledge, exchange insights, and forge collaborative solutions. This meeting offers a unique platform to connect with peers, researchers, and healthcare professionals dedicated to advancing our cause.



The scientific program of the Symposium is designed to include lectures from world known experts, oral and poster presentations and thematic round table discussions. We believe that this structure will facilitate and enhance the knowledge and clinical skills of the participants and aim to provide better care to our patients globally.

Thessaloniki, with its history dating back to ancient times and its vibrant spirit, is an inspiring setting for our meeting. It serves as a reminder that even in the face of adversity, this city has persevered and thrived.

We welcome you all to share in our knowledge and experiences and to promote international collaboration.

On behalf of the IPPF and the Organizing Committee

Marc Yale
IPPF Advocacy &
Research Coordinator

Aikaterini Patsatsi
Chair of the Organizing Committee

Patrick Dunn
IPPF Executive Director



ABOUT IPPF

The Four Pillars of the IPPF

1

Patient Support

The IPPF offers a variety of free patient services to help you live an active, productive life. These include our Peer Coach program, Patient Education Webinars, local and regional support groups, Find a Doctor list, annual Patient Education Conferences, and educational resources. These are just some of the ways to connect with the pemphigus and pemphigoid (P/P) community.

2

Awareness

The IPPF Biopsies Save Lives program seeks to accelerate diagnosis time of pemphigus and pemphigoid (P/P) patients. The average P/P patient sees five doctors over ten months in search of a correct diagnosis. Since the majority of P/P patients present oral symptoms first, the Biopsies Save Lives program focuses on pemphigus vulgaris (PV) and mucous membrane pemphigoid (MMP)-two forms of P/P with increased presentation in the mouth. PV/MMP patients often see a dentist as one of their first clinician contacts. Outreach is therefore directed to dental professionals through student and continuing education, who have the unique opportunity to shorten diagnosis times.

3


Research

Before new treatment therapies can be developed, investigators need to better estimate the prevalence of P/P, study their pathophysiology, understand treatment patterns, and assess the burden of these diseases on patients. The IPPF encourages research by conducting our Natural History Study, hosting scientific symposia, periodically offering research grants, and maintaining a library of clinical trial information for researchers and healthcare professionals.

4

Advocacy

Advocacy is defined as public support or recommendation for a particular cause. Advocacy is different from lobbying, which looks to influence a particular elected official or legislation. Advocacy can take place on local, state, or federal levels of government. The IPPF mainly advocates for patients at the federal level, but we encourage our community to support grassroots efforts through various umbrella organizations.



MEETING OF THE INTERNATIONAL PEMPHIGUS & PEMPHIGOID FOUNDATION



THESSALONIKI Greece **2024**

THE MEETING IS HELD UNDER THE AUSPICES OF

ΕΛΛΗΝΙΚΗ
ΔΕΡΜΑΤΟΛΟΓΙΚΗ
ΚΑΙ
ΑΦΡΟΔΙΣΙΟΛΟΓΙΚΗ
ΕΤΑΙΡΕΙΑ



HELLENIC
SOCIETY OF
DERMATOLOGY
AND
VENEREOLOGY




Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης
Σχολή Επιστημών Υγείας, Τμήμα Ιατρικής



ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ ΑΝΟΣΟΛΟΓΙΑΣ
HELLENIC SOCIETY OF IMMUNOLOGY



Ι Δ Ρ Υ Μ Α
Π Α Π Α Γ Ε Ω Ρ Γ Ι Ο Υ



FACULTY MEMBERS

Angelicas, Emmanuel

The Australian Museum of Contemporary Photography Australia

Antiga, Emiliano

Associate Professor of Dermatology, Department of Health Sciences, University of Florence, Italy

Aoki, Valeria

M.D., PhD., Associate Tenured Professor, Department of Dermatology, President of the International Relations Office University of Sao Paulo School of Medicine, São Paulo, SP Brazil

Apalla, Zoe

PhD, Professor of Dermatology, Second Dermatology Department, Aristotle University of Thessaloniki, Greece

Athanassopoulou-Lazarou, Vicky

MD, resident in Dermatology & Venereology, 2nd Department of Dermatology, National and Kapodistrian University of Athens, Attikon University Hospital, Greece

Borradori, Luca

Prof. Dr. Med., Dermatology Department, University Hospital of Bern, Switzerland

Caproni, Marzia

Professor of Dermatology Florence, Italy

Caux, Frederic

Head of the Department of Dermatology, Avicenne Hospital, University Paris 13, France

Chasapi, Vassiliki

MD, MSc, PhD, Director of Dermatology-Venereology Head of the Department of Dermatology and Venereology National Health System Andreas Sygros Hospital, Athens, Greece

Culton, Donna A.

MD, PhD, Associate Professor of Dermatology, University of North Carolina, United States

Daneshpazhooh, Maryam

Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

De, Dipankar

Prof. Dr. Med., Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Drenovska, Kossara

Associate Professor, MD, PhD Department of Dermatology and Venereology, Medical University-Sofia, Bulgaria

Dunn, Patrick

Executive Director, International Pemphigus & Pemphigoid Foundation

Efthymiadis, Konstantinos

Consultant, NHS Dermatology Department Hospital for Skin and Venereal Diseases, Thessaloniki, Greece

Ellebrecht, Christoph

Assistant Professor of Dermatology University of Pennsylvania United States

Fairley, Janet A.

MD, Professor Emeritus Department of Dermatology University of Iowa, United States

Gaitanis, Georgios


Ass. Professor, Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences University of Ioannina, Greece

Gidarokosta, Polyxeni

MD PhD, Consultant Dermatologist Department of Dermatology University Hospital of Larissa Greece

Grando, Sergei A.

MD, PhD, DSc, Distinguished Professor, Department of Dermatology, Department of Biological Chemistry, Cancer Center & Research Institute Institute for Immunology Director of the Immunobullous Clinic, University of California Irvine



FACULTY MEMBERS

Grigoriou, Stamatis

Associate Professor of
Dermatology-Venereology
National and Kapodistrian
University of Athens, Faculty of
Medicine, Andreas Sygros Hospital,
Athens, Greece

Hammers, Christoph

Professor for Rare Diseases
University of Regensburg /
University of Luebeck, Germany

Hertl, Michael

Prof. Dr. med., Director of
Dermatology and Allergology
Department, Philipps University /
University Hospital Marburg
Germany

Holtsche, Maïke Marleen

Senior Physician, University
Clinic of Dermatology and
Allergy, University of Oldenburg,
Oldenburg, Germany
Department of Dermatology,
University of Lübeck, Lübeck,
Germany

Ioannides, Dimitrios

Professor of Dermatology-
Venereology, Aristotle University
School of Medicine, Thessaloniki,
Greece

Joly, Pascal

Professor, Dermatology
Department, Rouen University
Hospital France

Katoulis, Alexander

Professor of Dermatology-
Venereology, Head of the 2nd
Department of Dermatology
and Venereology, National and
Kapodistrian University of Athens,
School of Medicine, University
General Hospital Attikon, Greece

Kiritsi, Dimitra

Ass. Professor of Dermatology
First Department of Dermatology,
Aristotle University of Thessaloniki,
Greece, Department of
Dermatology, Medical Center-
University of Freiburg, Germany

Koga, Hiroshi

Dr., Ph.D., Department of
Dermatology, Kurume University
School of Medicine, Japan

Kousta, Fiori

Dermatologist- Venereologist,
Director of NHS, Andreas Sygros
Hospital, Athens, Greece

Krasagakis, Konstantinos

MD, Professor of Dermatology
School of Medicine, University
of Crete, Greece, Head of the
Department of Dermatology
University General Hospital of
Heraklion, Crete, Greece

Kyrmanidou, Eirini

Academic Fellow, 2nd Department
of Dermatology and Venereology
Aristotle University of Thessaloniki,
Greece

Lazaridou, Elizabeth

Professor of Dermatology-
Venereology, Head, 2nd Department
of Dermatology-Venereology
Aristotle University School of
Medicine, Thessaloniki, Greece

Marinovic, Branka

Professor, Md, PhD, Head of the
Department of Dermatology and
Venereology, University Hospital
Center Zagreb, School of Medicine
University of Zagreb, Croatia

Mascaro Jr., Jose M.


Professor and Consultant
Department of Dermatology,
Hospital Clínic of Barcelona
Barcelona University Medical
School, Barcelona, Spain

Maverakis, Emanuel

Professor, Director, Immune
Monitoring Shared Resource
University of California, Davis
United States

Mosam, Anisa

Associate Professor, Department
of Dermatology, Nelson R Mandela
School of Medicine, University of
KwaZulu-Natal and Head Clinical
Unit Dermatology, Inkosi Albert
Luthuli Central Hospital, South
Africa



FACULTY MEMBERS

Murrell, Dedee F.

MA (Cambridge) BMBCCh (Oxford)
FAAD (USA) MD (UNSW) FACD
FRCP (Edin) DSc (Oxford)
Professor, Faculty of Medicine,
UNSW Medical School, Sydney,
Australia, Head, Dept of
Dermatology, St George Hospital
Campus, Kogarah, Sydney,
Australia, Professorial Fellow
(Honorary), The George Institute
for Global Health, Sydney
Chair, Communications Committee,
EADV, President, Australasian
Blistering Diseases Foundation
Board member, International
Society of Dermatology & CoChair
of Global Outreach Task Force

Nar, Leon A.

Phd, Modern Greek Literature,
Aristotle University of Thessaloniki
- Writer, Thessaloniki, Greece

Nicolaidou, Electra

Professor of Dermatology and
Venereology, 1st Department of
Dermatology and Venereology,
Medical School, National and
Kapodistrian University of Athens,
Andreas Sygros Hospital,
Athens, Greece

Pan, Meng

Md., Phd., Professor of Dermatology,
Doctoral Supervisor, Rui Jin
hospital, Shanghai Jiao Tong
University School of Medicine,
China

Panagakis, Pantelis

Dermatology - Venereology
Director of Dermatology Clinic
Andreas Sygros Hospital
Athens, Greece

Papadavid, Evangelia

MF, PhD, Professor in Dermatology
Chair of Cutaneous Lymphomas
Group EORTC, Director of National
Centre of Excellence for Rare
diseases/Cutaneous Lymphoma-
ERN BloodNet member
2nd Department of Dermatology
National and Kapodistrian
University of Athens, Attikon
University Hospital, Greece

Papakonstantis, Markos

Dermatologist, Director of
Dermatology Department,
401 Military General Hospital of
Athens, Greece

Papoutsaki, Marina

MD, PhD, Dermatologist, Director
of Dermatology Department,
Andreas Sygros Hospital,
Athens, Greece

Paschou, Eleni

MD, PhD, 1st Department of
Dermatology, Aristotle University
of Thessaloniki, Greece

Patsatsi, Aikaterini

MD, MSc, PhD, Professor of
Dermatology, Autoimmune Skin
and Bullous Diseases Unit
Center of Expertise on AIBD
2nd Dermatology Department
Aristotle University School of
Medicine, Papageorgiou General
Hospital, Thessaloniki, Greece

Payne, Aimee S.

MD, PhD, Herbert and Florence
Irving Professor and Chair of
Dermatology, Columbia University,
New York, United States

Pincelli, Carlo

Professor of Dermatology and
Venereology, School of Medicine
University of Modena and Reggio
Emilia, Modena, Italy

Routsis, Eleni

Resident in Dermatology and
Venereology, Andreas Sygros
Hospital, Athens, Greece

Saleh, Marwah Adly

M.D., Ph.D, Professor of Dermatology,
Cairo University, Egypt

Schmidt, Enno

M.D., Ph.D., University of Lübeck
Lübeck Institut of Experimental
Dermatology, Germany

Sidiropoulos, Theodoros


Director, NHS Dermatology
Department Hospital for Skin and
Venereal Diseases, Thessaloniki,
Greece

Sinha, Animesh A.

M.D., Ph.D., Professor, Department
of Dermatology, Jacobs School of
Medicine and Biomedical Science,
University at Buffalo, Buffalo, NY,
United States

Solimani, Farzan

Dr. Med., Clinic For Dermatology,
Allergology And Venereology
Charité - Universitätsmedizin
Berlin, Germany



FACULTY MEMBERS

Sotiriou, Elena

Professor of Dermatology
Venereology, Head of First
Dermatology Department
Aristotle University Thessaloniki,
Greece

Sotiropoulou, Kalliopi

Resident in Dermatology and
Venereology, National and
Kapodistrian University of Athens
Andreas Sygros Hospital of
Venereal and Dermatological
Diseases, Athens, Greece

Sprecher, Eli

MD, PhD, MBA, Professor and Chair,
Division of Dermatology
Deputy Director General for R&D
and Innovation, Tel Aviv Sourasky
Medical Center, Frederick Reiss
Chair of Dermatology
Department of Human Molecular
Genetics & Biochemistry
Vice Dean for Clinical Affairs
Faculty of Medicine, Tel Aviv
University, Tel Aviv, Israel

Stratigos, Alexander J.

MD, Professor of Dermatology
& Venereology, Chairman, First
Department of Dermatology-
Venereology, Andreas Sygros
Hospital, National and Kapodistrian
University of Athens, Athens,
Greece, Immediate Past President,
European Academy
of Dermatology-Venereology
(2022-2024), Athens, Greece

Tanga, Panagiota

MD, Resident in Dermatology and
Venereology, 401 General Military
Hospital of Athens, Greece

Tasanen, Kaisa

Professor and Chair, Department of
Dermatology, Head of the Research
Unit of Clinical Medicine
University of Oulu, Finland

Trakatelli, Myrto-Georgia

Professor of Dermatology-
Venereology, 2nd Department
of Dermatology, Aristotle
University School of Medicine,
Thessaloniki, Greece

Trigoni, Anastasia

Dermatologist - Venereologist
1st Attending Physician
MD, MSc, PhD, 2nd Department of
Dermatology and Venereology
Aristotle University of Thessaloniki
Papageorgiou Hospital, Greece

Tull, Thomas

St John's Institute of Dermatology,
London, United Kingdom

Uzun, Soner

Professor, MD, Akdeniz University
Faculty of Medicine, Department
of Dermatology & Venereology
Antalya, Turkey

Vakirlis, Efstratios

MD, PhD, Associate Professor of
Dermatology and Venereology
Aristotle University of Thessaloniki,
Greece

van Beek, Nina

Dr. med., University of Lübeck
Department Of Dermatology,
Allergology and Venerology
Germany

Vassileva, Snejina

MD, PhD, Professor, Department
of Dermatology and Venereology
Sofia University of Medicine
Sofia, Bulgaria

Vielmuth, Franzisca

Group Leader, Institute of
Anatomy, Faculty Of Medicine
LMU, Munich, Germany

Waschke, Jens

Professor. Dr., Institute of Anatomy
and Cell Biology, LMU
Munich, Germany

Werth, Victoria P.

M.D., Professor of Dermatology
University of Pennsylvania,
United States

Yale, Marc

IPPF Advocacy & Research
Coordinator

Yamagami, Jun


Professor, Department of
Dermatology, Tokyo Women's
Medical University, Japan

Yayli, Savaş

MD, Professor in Department
of Dermatology, Koç University
School of Medicine, Istanbul Turkey

Zafiriou, Efterpi

Associate Professor of Dermatology
University Hospital of Larissa
School of Health Science
University of Thessaly, Greece



PROGRAM AT-A-GLANCE

THURSDAY, AUGUST 29, 2024 - PEMPHIGUS DAY	
09:00-09:15	Welcome
09:15-10:30	From Pemphix to Pemphigus - Invited Lectures
10:30-11:00	Coffee Break
11:00-12:30	Interesting cases from around the world
12:30-13:00	Keynote Lecture
13:00-13:45	Selected Abstracts - Oral Presentations
13:45-14:30	Lunch Break
14:30-16:00	Pemphigus - Treatment update
16:30-18:00	Opening Ceremony Opening Lectures <ul style="list-style-type: none"> • The impact of 30 years suffering from an AIBD: Shaking hands with the devil - living with EBA • The future of the past, imprints of history on the fabric of Thessaloniki
18:00-19:00	Welcome Reception
FRIDAY, AUGUST 30, 2024 - PEMPHIGOID DAY	
09:00-10:30	From Pemphix to Pemphigoid Diseases - Invited Lectures
10:30-11:00	Coffee Break
11:00-12:30	Interesting cases from around the world
12:30-13:30	Selected Abstracts - Oral Presentations
13:30-14:30	Lunch Break
14:30-15:30	Pemphigoid Diseases - Treatment Update
15:30-18:00	Optimal designs for BP and pemphigus studies - discussion on clinical trial endpoints - Group discussion
SATURDAY, AUGUST 31, 2024	
09:00-11:00	Autoimmune Bullous Diseases - Selected Abstracts - Oral Presentations
11:00-11:30	Coffee Break
11:30-12:30	Meet the Experts
SESSION IN GREEK	
12:30-13:00	Psoriasis Δύσκολες στη διαχείριση μορφές ψωρίασης
13:00-13:30	Hidradenitis Suppurativa Δύσκολες στη διαχείριση περιπτώσεις διαπυθκτικής ιδρωταδενίτιδας
13:30-14:00	Epidermolysis Bullosa Πομφολυγώδης Επιδερμόλυση
14:00-14:30	Atopic Dermatitis - New treatments Ατοπική Δερματίτιδα - Εμπειρία από τις νέες θεραπείες
14:30-15:30	Lunch Break
15:30-16:00	Vitiligo - New treatments Λεύκη και ανταπόκριση στις νέες θεραπείες
16:00-16:30	Alopecia Areata and Jak inhibitors Γυροειδής Αλωπεκία και Jak αναστολείς
16:30-17:00	Closing Remarks

SCIENTIFIC PROGRAM

THURSDAY, AUGUST 29, 2024	14-16
FRIDAY, AUGUST 30, 2024	17-20
SATURDAY, AUGUST 31, 2024	21-23
SATURDAY, AUGUST 31, 2024 SESSION IN GREEK	24-26

PEMPHIGUS DAY

THURSDAY, AUGUST 29, 2024

09:00-09:15	<p>Welcome Chairs: Aikaterini Patsatsi, Marc Yale, Patrick Dunn</p>
09:15-10:30	<p>From Pemphix to Pemphigus - Invited Lectures Chairs: Animesh Sinha, Jens Waschke</p> <p>Genetics in Pemphigus Eli Sprecher</p> <p>Pathogenesis of pemphigus Franziska Vielmuth</p> <p>Auto-reactive B cells in pemphigus Jun Yamagami</p> <p>Fogo selvagem Valeria Aoki</p>
10:30-11:00	<p>Coffee Break</p>
11:00-12:30	<p>Interesting cases from around the world Chairs: Branka Marinovic, Alexander Stratigos</p> <p>Pemphigus in Iran: A Look at Interesting Cases Maryam Daneshpazhooh, <i>Iran</i></p> <p>Interesting case from India Dipankar De, <i>India</i></p> <p>IgG/IgA pemphigus: a rare pustular eruption Savas Yayli, <i>Turkey</i></p> <p>IgA pemphigus and anti-desmocollin antibody in pemphigus Hiroshi Koga, <i>Japan</i></p> <p>Interesting Cases from South Africa Anisa Mosam, <i>South Africa</i></p>
12:30-13:00	<p>Keynote Lecture Chair: Dedee Murrell</p> <p>The glycan theory of autoimmunity and glycan alterations in pemphigus Emanual Maverakis</p>

13:00-13:45

Selected Abstracts - Oral Presentations

Chairs: Aimee Payne, Victoria Werth

OR. 01 - PAPER NUMBER: 45

Prevalence of Herpes Simplex Virus Infection in Patients with Pemphigus Vulgaris
Hanmei Zhang, Suying Feng

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China

OR. 02 - PAPER NUMBER: 52

CD4 + T cells immunophenotyping predicts relapse in Pemphigus Vulgaris patients treated with Rituximab as adjuvant therapy: a retrospective study

Simone Liguori¹, Daniela Adamo¹, Elvira Ruoppo¹, Antonia Fiore², Rosa Manganiello², Lucia Mauriello², Michele Davide Mignogna¹, Stefania Leuci¹

¹Department of Neuroscience, Reproductive and Odontostomatological Sciences, Oral Medicine Unit, University of Naples Federico II, Naples, Italy, ²Clinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE, Naples, Italy

OR. 03 - PAPER NUMBER: 57

Reliability and validity of investigator global assessment (IGA) scores for assessing severity of pemphigus

Darby Boucher¹, **Anna Wilson^{1,2}**, Maryam Daneshpazhooh³, Nisha S Chandran⁴, Snežina Vassileva⁵, Kossara Drenovska⁵, Aikaterini Patsatsi⁶, Asli Bilgic⁷, Donna A Culton⁸, Aimee S Payne⁹, Pascal Joly¹⁰, Eli Sprecher¹¹, Enno Schmidt^{12,13}, Nina Van Beek¹², Yen L Lim¹⁴, Dario Didona¹⁵, Angelo V Marzano^{16,17}, Jun Yamagami¹⁸, Frederic Caux¹⁹, Branka Marinovic²⁰, Boaz Shulruf¹, Dedee F Murrell^{1,2}

¹Faculty of Medicine, University of NSW, Sydney, Australia, ²Department of Dermatology, St George Hospital, Sydney, Australia, ³Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran, ⁴Division of Dermatology, Department of Medicine, National University Hospital, Singapore, Singapore, ⁵Department of Dermatology and Venereology, University Hospital "Alexandrovska", Medical University - Sofia, Sofia, Bulgaria, ⁶Second Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece, ⁷Department of Dermatology and Venereology, Akdeniz University School of Medicine, Antalya, Turkey, ⁸Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, USA, ⁹Department of Dermatology, Columbia University, New York, USA, ¹⁰Department of Dermatology, Rouen University Hospital, Rouen, France, ¹¹Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹²Department of Dermatology, University of Lübeck, Lübeck, Germany, ¹³Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany, ¹⁴National Skin Centre, Singapore, Singapore, ¹⁵Department of Dermatology, University of Marburg, Marburg, Germany, ¹⁶Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ¹⁷Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, ¹⁸Department of Dermatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁹Department of Dermatology, Avicenne Hospital, University of Paris 13, Bobigny, France, ²⁰Department of Dermatology and Venereology, School of Medicine, University Hospital Centre Zagreb, University of Zagreb, Zagreb, Croatia

PEMPHIGUS DAY

THURSDAY, AUGUST 29, 2024

OR. 04 - PAPER NUMBER: 13

Precision in pemphigus treatment assessment: Establishing minimal clinically important differences (MCIDs) for the pemphigus disease area index (PDAI)

Henry Tseng^{1,2}, Corey Stone^{1,2}, Boaz Shulruf², Dedee Murrell^{1,2}

¹Department of Dermatology, St George Hospital, Sydney, Australia, ²Faculty of Medicine, University of New South Wales, Sydney, Australia

OR. 05 - PAPER NUMBER: 68

Large scale autoantibody profiling identifies actionable biomarkers linked to multiple disease parameters that can be used in predictive machine learning algorithms

Rebekah R. Schwartz, Kristina Seiffert-Sinha, **Animesh A. Sinha**

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, United States

OR. 06 - PAPER NUMBER: 6

Psychosocial Burden of Autoimmune Blistering Diseases (AIBD): A Comprehensive Survey Study Examining Psychiatric Comorbidity, Quality of Life, and Body Image

Marney White, Victoria Hoffman, Marc Yale, Rebecca Strong, Mary Tomayko

Yale School of Public Health; Yale School of Medicine, New Haven, United States

13:45-14:30

Lunch Break

14:30-16:00

Pemphigus - Treatment update

Chairs: Sergei Grando, Dimitrios Ioannides, Christoph Ellebrecht

The best way to use rituximab in pemphigus vulgaris and foliaceus

Pascal Joly

FcRN inhibitors for pemphigus

Dedee Murrell

DSG3-CAART molecular and correlative profiling: lessons from a first-in-human study

Aimee Payne

Fas ligand inhibitors

Carlo Pincelli

T regulatory cells and their potential role in the treatment of pemphigus

Michael Hertl

16:30-18:00

Opening Ceremony

Chairs: Aikaterini Patsatsi, Marc Yale, Patrick Dunn

Opening Lectures

- **The impact of 30 years suffering from an AIBD: Shaking hands with the devil - living with EBA**

Emmanuel Angelicas

- **The future of the past, imprints of history on the fabric of Thessaloniki**

Leon Nar

18:00-19:00

Welcome Reception

PEMPHIGOID DAY

FRIDAY, AUGUST 30, 2024

09:00-10:30

From Pemphix to Pemphigoid Diseases - Invited Lectures

Chairs: Jose Mascaro, Christoph Hammers

Pathophysiology of Bullous Pemphigoid

Christoph Hammers

Pathophysiology of pemphigoid diseases other than BP

Enno Schmidt

Association of BP with neurologic disease / DPPIvis

Kaisa Tasanen

Novel developments in the diagnosis of AIBD

Nina Van Beek

10:30-11:00

Coffee Break

11:00-12:30

Interesting cases from around the world

Chairs: Snejina Vassileva, Elizabeth Lazaridou, Soner Uzun

Interesting case from UK

Thomas Tull, *St. Johns*

Interesting case from Germany

Farzan Solimani, *Berlin*

Unilateral Hand Pustules and Erosions in a 57-year-old female

Marwah Saleh, *Cairo*

Anti-p200 pemphigoid as a differential diagnosis for erythema multiforme majus

Maike HOLTSCHE, *Oldenburg*

Mucous membrane pemphigoid misdiagnosed as oral lichen planus: a case and review of lichenoid histologic findings in mucous membrane pemphigoid

Donna Culton, *USA*

12:30-13:30

Selected Abstracts - Oral Presentations

Chairs: Pascal Joly, Enno Schmidt

OR. 07 - PAPER NUMBER: 37

Pathogenic potential of $\alpha 6$ and $\beta 4$ integrin antibodies in mucous membrane pemphigoid in vitro and in vivo

Sabrina Patzelt¹, Shirin Emtenani¹, Gefei Du^{1,2,3}, Dennis Niese¹, Aysun Gökce¹, Maxi Hofrichter¹, Charlotte Kiehne¹, Ferdinand Gebauer¹, Ralf J. Ludwig¹, Tephane Goletz¹, Gang Zhou^{2,3}, Enno Schmidt^{1,4}

¹Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany, ²State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, China, ³Department of Oral Medicine, School and Hospital of Stomatology, Wuhan University, Wuhan, China, ⁴Department of Dermatology, Allergology and Venerology, University of Lübeck, Lübeck, Germany

OR. 08 - PAPER NUMBER: 23

Reactivity against the BP180 ectodomain in patients with bullous pemphigoid, mucous membrane pemphigoid, multiple sclerosis and Parkinson disease

Maurizio Romagnuolo^{1,2}, Jonathan Tegtmeier^{1,3}, Cristoph M. Hammers^{1,4}, Bianca Opelka¹, Christian Probst⁵, Lars Komorowski⁵, Angelo V. Marzano^{2,6}, Enno Schmidt^{1,4}, Stephanie Goletz¹

¹Lübeck Institute for Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany, Lübeck, Germany, ²Fondazione IRCCS Ca' Granda, Ospedale Maggi, Milano, Italy, ³Clinic and Polyclinic for Dermatology and Venereo, Hamburg, Germany, ⁴Department of Dermatology, Allergology and Venerology, University of Lübeck, Lübeck, Germany, , Germany, ⁵Institute of Experimental Immunology, EUROIMMUN AG, Lübeck, Germany, Germany, ⁶Dermatology Unit, Department of Pathophysiology and Transplantation, University of Milan, Italy, Italy

OR. 09 - PAPER NUMBER: 4

Association of gene COL17A1's variations rs805708, rs805722 and rs17116350 with the development of bullous pemphigoid in patients with neurodegenerative disorders

Parthena Meltzanidou¹, Antonios Fantakis², Vassileva Snejina³, Drenovska Kossara³, Georgia Deretzi⁴, Aikaterini Chatzopoulou⁵, Alexandros Lampropoulos⁶, Maria Syrrou⁷, Elisavet Lazaridou¹, Aikaterini Patsatsi¹

¹B' Dermatology Clinic, AUTH, Papageorgiou General Hospital, Thessaloniki, Greece, ²1st Department of Surgery, AUTH, Papageorgiou General Hospital, Thessaloniki, Greece, ³Department of Dermatology and Venereology, University Hospital "Alexandrovska", Medical university of Sofia, Sofia, Bulgaria, ⁴Department of Neurology, Papageorgiou General Hospital, Thessaloniki, Greece, ⁵Department of Electrical Engineering and Electronics, School of Electrical Engineering, Electronics and Computer Science, University of Liverpool, Liverpool, United Kingdom, ⁶Laboratory of Medical Biology and Genetics, School of Medicine, Faculty of Health Sciences, AUTH, Thessaloniki, Greece, ⁷Laboratory of Biology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

OR. 10 - PAPER NUMBER: 46

Prevalence and Clinical Markers of Herpes Simplex Virus Infection in Oral Lesions of Bullous Pemphigoid

Hanmei Zhang, Suying Feng

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China

OR. 11 - PAPER NUMBER: 22

A retrospective cohort study of checkpoint inhibitors induced bullous pemphigoid

Anastasia Tsitlakidou, Ch. Kemanetzi, Eirini Kyrmanidou, C. Papageorgiou, Aikaterini Patsatsi, Elisabeth Lazaridou, Zoi Apalla

Second Dermatology Department, Aristotle University of Thessaloniki, Greece, Thessaloniki, Greece

OR. 12 - PAPER NUMBER: 36

Development of first-in-class monoclonal antibody therapy for treatment of the Linear IgA Dermatitis (LAD)

Aleksandra Cegiel, Dawid Łyzwa

JJP Biologics, Warsaw, Poland

OR. 13 - PAPER NUMBER: 5

Autoimmune Blistering Diseases Treated with Glucocorticoids: An International Study of Steroid-Induced Myopathy

Ailin He^{1,2}, Ben Koszegi^{1,2}, Soner Uzun³, Asli Bilgic³, Burcin Canzu Bozca³, Baoqi Yang⁴, Maryam Daneshpazhooh⁵, Maria Boziou⁶, Aikaterini Patsatsi⁶, Risa Kakuta⁷, Hayato Takahashi⁷, Dana Nery⁸, Camille Mundin⁸, Mae Ramirez-Quizon⁸, Donna Culton⁹, Sarah McAlpine⁹, Joslin Johal^{1,2}, Boaz Shulruf², John Stone¹⁰, Dedee Murrell^{1,2}

¹Department of Dermatology, St George Hospital, Sydney, Australia, ²Faculty of Medicine, UNSW, Sydney, Australia, ³Department of Dermatology and Venereology, Akdeniz University, Antalya, Turkey, ⁴Shandong Provincial Hospital for Skin Diseases, Jinan, China, ⁵Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran, Iran, ⁶Second Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece, ⁷Department of Dermatology, Keio University School of Medicine, Tokyo, Japan, ⁸Department of Dermatology, Rizal Medical Center, Philippines, ⁹Department of Dermatology, University of North Carolina, Chapel Hill, United States, ¹⁰Division of Rheumatology, Massachusetts General Hospital and Harvard Medical School, Boston, United States

OR. 14 - PAPER NUMBER: 56

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoabsorption. A prospective monocenter pilot study

Maike Marleen Holtsche¹, Nina van Beek¹, Michael Kasperkiewicz², Nina Schumacher¹, Inke König³, Philip Muck⁴, Enno Schmidt^{1,5}

¹Department of Dermatology, University of Lübeck, Lübeck, Germany, ²Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, ³Institute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany, ⁴Department of Internal Medicine, University of Lübeck, Lübeck, Germany, ⁵Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany

13:30-14:30

Lunch Break

PEMPHIGOID DAY

FRIDAY, AUGUST 30, 2024

14:30-15:30

Pemphigoid Diseases - Treatment Update

Chairs: Janet Fairley, Marzia Caproni

Unmet needs in patients with pemphigoid diseases: current gaps

Luca Borradori

Emerging therapies for MMP, LAD and EBA

Frederic Caux

Dupilumab in BP - what's the evidence

Meng Pan

The role of anti IgE treatment

Janet Fairley

15:30-18:00

Optimal designs for BP and pemphigus studies - discussion on clinical trial endpoints - Group discussion

Chairs: Aikaterini Patsatsi, Marc Yale

Lessons about optimal designs for BP and pemphigus studies - Approved endpoints for clinical trials - a comparison of autoimmune diseases

Victoria Werth

Pitfalls in trials of steroid alternatives for AIBD

Dedee Murrell

SATURDAY, AUGUST 31, 2024

09:00-11:00	<p>Autoimmune Bullous Diseases – Selected Abstracts – Oral Presentations Chairs: Elena Sotiriou, Emiliano Antiga, Kosara Drenovska, Dimitra Kiritsi</p>
<p>OR. 15 – PAPER NUMBER: 67</p>	
<p>Expanding the understanding of Dsg3-mediated mechanical signaling in pemphigus vulgaris Siavash Rahimi¹, William VJ Hariton¹, Sen Guo², Giacomo Paccagnan³, Lorenzo Scipioni⁴, Giulia Tedeschi⁴, Patrizia Sauta¹, Taravat Shojaeian¹, Veronika Hartmann², Christoph M Hammers², Jennifer E Hundt², Tomaso Zambelli³, Ralf J Ludwig², Hauke Busch², Luca Borradori¹, Eliane Jasmine Müller¹ <i>¹Department of Biomedical Research and Department of Dermatology, Inselspital, University of Bern, ²Lübeck Institute of Experimental Dermatology, University of Lübeck, ³Laboratory of Biosensors and Bioelectronics, Institute for Biomedical Engineering, ETH Zurich, ⁴Laboratory for Fluorescence Dynamics, University of California, Irvine</i></p>	
<p>OR. 16 – PAPER NUMBER: 89</p>	
<p>Comprehensive analysis of T cell distribution and T-cell receptor repertoire in endemic pemphigus foliaceus Verónica Calonga-Solís¹, Ticiana Farias¹, Ivan Wolf¹, Gabriel Cipolla², Danielle Malheiros², Maria-Luiza Petzl-Erler², Danillo Augusto¹ <i>¹University of North Carolina Charlotte, ²Universidade Federal do Paraná</i></p>	
<p>OR. 17 – PAPER NUMBER: 29</p>	
<p>Single-cell long-read sequencing analysis in endemic pemphigus foliaceus Ticiana Farias¹, Verónica Calonga-Solís¹, Ivan Wolf¹, Gabriel Cipolla², Danielle Malheiros², Dr. Maria-Luiza Petzl-Erler², Danillo Augusto¹ <i>¹University of North Carolina Charlotte, ²Universidade Federal do Paraná</i></p>	
<p>OR. 18 – PAPER NUMBER: 35</p>	
<p>Characterization and pharmacological inhibition of an adult antibody-transfer mouse model of pemphigus vulgaris Shirin Emtenani¹, Maxi Hofrichter¹, Lars Komorowski², Christian Probst², Sabrina Patzelt¹, Enno Schmidt^{1,3} <i>¹Lübeck Institute of Experimental Dermatology, University of Lübeck, ²Institute of Experimental Immunology, EUROIMMUN AG, ³Department of Dermatology, University of Lübeck</i></p>	
<p>OR. 19 – PAPER NUMBER: 21</p>	
<p>Integration of single-cell and bulk profiling reveals the heterogeneity and tumor microenvironment in unicentric Castleman disease associated with paraneoplastic pemphigus Sai Wang, Mingyue Wang <i>Peking University First Hospital</i></p>	
<p>OR. 20 – PAPER NUMBER: 70</p>	
<p>Single-cell and multiparameter immunome analysis highlights the role of the Th17 pathway in Pemphigus pathogenesis Isabelle Kozik, Kristina Seiffert-Sinha, Animesh A. Sinha <i>Jacobs School of Medicine and Biomedical Sciences, University at Buffalo</i></p>	

SATURDAY, AUGUST 31, 2024

OR. 21 - PAPER NUMBER: 69

Healthy individuals who are genetically related to patients with either Pemphigus vulgaris or Alopecia areata exhibit disease-like cytokine dysregulation

Rebekah R. Schwartz, Kristina Seiffert-Sinha, **Animesh A. Sinha**
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

OR. 22 - PAPER NUMBER: 7

A case of paraneoplastic anti-laminin 332-type mucous membrane pemphigoid treated with an immune checkpoint inhibitor

Meropi Karakioulaki, Frank Meiß, Kilian Eyerich, Franziska Schauer
Department of Dermatology and Venereology, Medical Center, University Hospital Freiburg, Germany

OR. 23 - PAPER NUMBER: 9

Clinical and immunological predictors of early relapse in Indian patients with pemphigus treated with rituximab: A prospective cohort study

Vishal Gupta¹, Rhea Ahuja¹, Shafaque Imran¹, Ganesh Kumar Vishwanathan², Manoj Kumar Tembhre³, Sujay Khandpur¹
¹Department of Dermatology and Venereology, All India Institute of Medical Sciences, ²Department of Hematology, All India Institute of Medical Sciences, ³Department of Cardiac Biochemistry, All India Institute of Medical Sciences

OR. 24 - PAPER NUMBER: 88

Lessons to learn from recalcitrant bullous pemphigoid - New therapeutic options

Georgios Kokolakis, Kamran Ghoreschi, Tereza Jakovljevicova, Farzan Solimani
Charité-Universitätsmedizin Berlin

OR. 25 - PAPER NUMBER: 14

A phenotype of mild Bullous Pemphigoid treated with dupilumab

Florentina-Silvia Delli¹, Zoe Apalla², Asimina Fylaktou³, Aikaterini Anastasiou³, Efstratios Vakirlis⁴, Dimitra Kyritsi⁴, Elisabeth Lazaridou², Elena Sotiriou⁴, Demetrios Ioannides⁴, Giorgos Chaidemenos¹
¹Hippokration General Hospital, ²Aristotle University, Second Department of Dermatology and Venereology, School of Medicine, ³National Peripheral Histocompatibility Center and Department of Immunology Hippokration General Hospital, ⁴Aristotle University, First Department of Dermatology and Venereology, School of Medicine

OR. 26 - PAPER NUMBER: 40

Evaluation of Dupilumab in Patients With Bullous Pemphigoid

Meng Pan
Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

OR. 27 - PAPER NUMBER: 47

Ofatumumab for the Treatment of Patients with Pemphigus Vulgaris: A Cohort Study Based on a Prospective Registry Database

Xiwen Zhang, Yiyi Wang, Wei Li
Department of Dermatology and Venereology & Rare Disease Center, West China Hospital, Sichuan University

SATURDAY, AUGUST 31, 2024

OR. 28 - PAPER NUMBER: 26

Examining the relationship between systemic glucocorticoid (GC) dose and GC-induced toxicity: An international study of patients with autoimmune blistering diseases

Joslin Johal^{1,2}, Ailin He^{1,2}, Timothy Cowan¹⁰, Soner Uzun³, Asli Bilgic³, Burcin Canzu Bozca³, Baoqi Yang⁴, Maryam Daneshpazhooh⁵, Maria Boziou⁶, Aikaterini Patsatsi⁶, Risa Kakuta⁷, Hayato Takahashi⁷, Dana Nery⁸, Camille Munding⁸, Mae Ramirez-Quizon⁸, Donna Culton¹¹, Sarah McAlpine¹¹, Ben Koszegi^{1,2}, John H Stone⁹, Dedee F Murrell^{1,2}

¹University of New South Wales, ²Department of Dermatology, St George Hospital, ³Department of Dermatology and Venereology, Akdeniz University, Faculty of Medicine, ⁴Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology & Shandong First Medical University & Shandong Academy of Medical Sciences, ⁵Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, ⁶Second Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, ⁷Department of Dermatology, Keio University School of Medicine, ⁸Department of Dermatology, Rizal Medical Center, ⁹Division of Rheumatology, Massachusetts General Hospital and Harvard Medical School, ¹⁰School of Medicine and Psychology, Australian National University, ¹¹Department of Dermatology, University of North Carolina

11:00-11:30

Coffee Break

11:30-12:30

Meet the Experts

Marc Yale, Patrick Dunn, all

SESSION IN GREEK

SATURDAY, AUGUST 31, 2024

12:30-13:00

Psoriasis**Δύσκολες στη διαχείριση μορφές ψωρίασης****Chairs:** Efterpi Zafiriou, Pantelis Panagakis, Marina Papoutsaki, Theodoros Sidiropoulos**Treatment of generalized pustular psoriasis with spesolimab****Αντιμετώπιση γενικευμένης φλυκταινώδους ψωρίασης με σπесоλιμάμπη**

Polyxeni Gidarokosta

Palmoplantar pustular psoriasis**Ακροφλυκταίνωση**

Eleni Routsis

Severe Psoriasis in a patient with Sarcoidosis and Bullous Pemphigoid**Σοβαρή κατά πλάκας ψωρίαση σε ασθενή με σαρκοείδωση και πομφολυγώδες πεμφιγοειδές**

Konstantinos Efthymiadis

13:00-13:30

Hidradenitis Suppurativa**Δύσκολες στη διαχείριση περιπτώσεις διαπυτυκτικής ιδρωταδενίτιδας****Chairs:** Alexander Katoulis, Anastasia Trigoni**OR. 29 | PAPER NUMBER: 12****Demographic Features of Hidradenitis Suppurativa: A Single-center Retrospective analysis of 357 patients in Northern Greece****Δημογραφικά Χαρακτηριστικά της Διαπυτυκτικής Ιδρωταδενίτιδας: Μονοκεντρική Αναδρομική Μελέτη Δεδομένων 357 Ασθενών στη Βόρεια Ελλάδα**Anastasia Trigoni¹, **Sofia-Andriani Theodorelou-Charitou**¹, Athina-Ioanna Daponte¹, Anna Vatalachou¹, Elisavet Mingiani¹, Fragkiski Tsatsou¹, Parthena Meltzanidou¹, Trifon Papadopoulos², Vasiliki Malamou³, Elisavet Lazaridou¹¹Hidradenitis Suppurativa Outpatient Clinic, Second Department of Dermatology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, ²Head Nurse, Clinical Research Unit Department, Papageorgiou General Hospital, ³School of Medicine, European University of Cyprus**OR. 30 | PAPER NUMBER: 27****Clinical Experience of Adalimumab Biosimilar Hyrimoz in Moderate to Severe Hidradenitis Suppurativa. Switching from Adalimumab Originator Humira to Hyrimoz****Κλινική εμπειρία χρήσης του βίο ομοειδούς της ανταλιμουμάμπης, Hyrimoz, στη μέτρια προς σοβαρή Διαπυτυκτική Ιδρωταδενίτιδα. Μεταβαίνοντας από το πρωτότυπο φάρμακο ανταλιμουμάμπης Humira, στο βίο ομοειδές Hyrimoz**Anastasia Trigoni¹, **Anna Vatalachou**¹, Sofia-Andriani Theodorelou-Charitou¹, Athina-Ioanna Daponte¹, Elisavet Mingiani¹, Fragkiski Tsatsou¹, Parthena Meltzanidou¹, Trifon Papadopoulos², Vasiliki Malamou³, Elisavet Lazaridou¹¹Hidradenitis Suppurativa Outpatient Clinic, Second Department of Dermatology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, ²Head Nurse, Clinical Research Unit Department, Papageorgiou General Hospital, ³Medical Student, European University of Cyprus**OR. 31 | PAPER NUMBER: 77****Bimekizumab in Hidradenitis Suppurativa: Real-world Insights from a 12-Month Study at a Tertiary Hospital in Northern Greece****Βιμεκίζουμαβ στη Διαπυτυκτική Ιδρωταδενίτιδα: κλινικά δεδομένα 12-μηνιαίας μελέτης τεταρτοβάθμιου νοσοκομείου της Βορείου Ελλάδας**Anastasia Trigoni¹, **Athina-Ioanna Daponte**¹, Anna Vatalachou¹, Sofia-Andriani Theodorelou-Charitou¹, Elisavet Mingiani¹, Parthena Meltzanidou¹, Elisabeth Lazaridou¹¹Hidradenitis Suppurativa Outpatient Clinic, Aristotle University of Thessaloniki, ²nd Department of Dermatology and Venerology, G.N Papageorgiou, Thessaloniki, Greece

SESSION IN GREEK

SATURDAY, AUGUST 31, 2024

13:30-14:00	<p>Epidermolysis Bullosa Πομφολυγώδης Επιδερμόλυση Chair: Konstantinos Krasagakis</p> <p>Epidermolysis Bullosa - The disease and the new treatment modalities Πομφολυγώδης Επιδερμόλυση - Η νόσος και οι νέες διαθέσιμες αγωγές Dimitra Kiritsi</p>
<p>OR. 32 PAPER NUMBER: 32</p>	
	<p>Epidermolysis Bullosa: Our experience with Oleogel-S10 Πομφολυγώδης Επιδερμόλυση - Η εμπειρία μας με το Oleogel-S10 Eirini Kyrmanidou, Christina Kemanetzi, Zoe Apalla, Elizabeth Lazaridou <i>Aristotle University of Thessaloniki</i></p>
14:00-14:30	<p>Atopic Dermatitis - New treatments Ατοπική Δερματίτιδα - Εμπειρία από τις νέες θεραπείες Chairs: Stamatis Grigoriou, Efstratios Vakirlis, Georgios Gaitanis</p> <p>Switching between novel treatments in AD when efficacy is not fulfilling expectations Αλλαγή μεταξύ των καινοτόμων θεραπειών όταν η αποτελεσματικότητα δεν είναι ικανοποιητική Stamatis Grigoriou</p> <p>Comorbidity of Atopic dermatitis Ατοπική δερματίτιδα και συννοσηρότητες Eleni Paschou</p> <p>The role of mycobiome in atopic dermatitis Ο ρόλος του μυκητώματος στην ατοπική δερματίτιδα Georgios Gaitanis</p>
14:30-15:30	<p>Lunch Break</p>
15:30-16:00	<p>Vitiligo - New treatments Λεύκη και ανταπόκριση στις νέες θεραπείες Chairs: Electra Nicolaidou, Markos Papakonstantis, Myrto-Georgia Trakatelli</p> <p>Vitiligo: Our experience with topical ruxolitinib Λεύκη: Η εμπειρία μας από την τοπική ρουξολιτινίμη Kalliopi Sotiropoulou</p> <p>Interesting Cases Παρουσίαση περιστατικών Panagiota Tanga</p>

SESSION IN GREEK

SATURDAY, AUGUST 31, 2024

16:00-16:30	<p>Alopecia areata and Jak inhibitors Γυροειδής αλωπεκία και JAK αναστολείς Chairs: Vassiliki Chasapi, Zoe Apalla, Evangelia Papadavid</p> <p>The experience from the department of hair diseases of A. Syggros Hospital, Athens Η εμπειρία από το τμήμα παθήσεων τριχών του Νοσοκομείου «Α. Συγγρός», Αθήνα Fiori Kousta</p> <p>The experience from the Hair Outpatient Clinic of Papageorgiou Hospital, Thessaloniki Η εμπειρία μας από το Ιατρείο Τριχών του Γ. Ν. Παπαγεωργίου Θεσσαλονίκης Eirini Kyrmanidou</p> <p>An interesting case Ενδιαφέρον περιστατικό Vicky Athanassopoulou-Lazarou</p>
16:30-17:00	<p>Closing Remarks Chairs: Aikaterini Patsatsi, Marc Yale, Patrick Dunn</p>

e-POSTERS

e-POSTERS

PO 1. | PAPER NUMBER: 1

The emerging role of T cells in pemphigus vulgaris: a systematic review

Farnaz Aaraghi

Skin Research Center of Shahid Beheshti University of Medical Sciences, Iran

PO 2. | PAPER NUMBER: 2

TEN/SJS-like lupus erythematosus presentation complicated by COVID-19

Farnaz Aaraghi

Skin Research Center of Shahid Beheshti University of Medical Sciences, Iran

PO 3. | PAPER NUMBER: 3

COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience

Farnaz Aaraghi

Skin Research Center of Shahid Beheshti University of Medical Sciences, Iran

PO 4. | PAPER NUMBER: 8

Treatment of a patient with severe dystrophic epidermolysis bullosa with Beremagene Geperpavec (B-VEC) gene therapy

Meropi Karakioulaki, Kilian Eyerich, Cristina Has

Department of Dermatology and Venereology, Medical Center, University Hospital Freiburg, Freiburg, Germany

PO 5. | PAPER NUMBER: 10

Characterizing Disability, Quality of Life, and Remission Status in Autoimmune Blistering Diseases

Marney White, Marc Yale, Rebecca Strong, Patrick Dunn, Isobel Davies, Laurence Gallu,

Aimee Payne, Victoria Werth, Dedee Murrell, Pascal Joly, Takashi Hashimoto

Yale School of Public Health; Yale School of Medicine, United States

PO 6. | PAPER NUMBER: 11

Pemphigoid Gestationis in Pregnancy Decoded

Rey Tristan Joshua Unay², **Marion Odette Alonzo**^{1,2}, **Jolene Kristine Dumlao**^{1,2,3}

¹Philippine Dermatological Society, Manila, Philippines, ²Southern Isabela Medical Center

Department of Dermatology and Venereology, Santiago City, Philippines, ³Dermatopathology

Society of the Philippines - Philippine Dermatological Society, Manila, Philippines

PO 7. | PAPER NUMBER: 15

Gene therapy for skin bullous diseases - where are we?

Florentina-Silvia Delli¹, Dimitra Kyritsi², Efstratios Vakirlis², Elena Sotiriou²

¹Hippokraton General Hospital, Greece, ²Aristotle University, First Department of Dermatology and Venereology, School of Medicine, Thessaloniki, Greece

PO 8. | PAPER NUMBER: 16

Psoriasis and Depression: The Role of Inflammation

Harrison Loftus, Mohammad Jafferany


Central Michigan University, United States

PO 9. | PAPER NUMBER: 17

Pemphigus Vulgaris: Patient-Centered Clinical Pearls

Harrison Loftus, Mohammad Jafferany

Central Michigan University, United States



e-POSTERS

PO 10. | PAPER NUMBER: 18

Netherthon Syndrome: therapeutic approach with dupilumab, our experience

Eirini Kyрманidou, Christina Kemanetzi, Aikaterini Patsatsi, Zoe Apalla, Elizabeth Lazaridou
Aristotle University of Thessaloniki, Greece

PO 11. | PAPER NUMBER: 19

Diagnosis of anti-p200 pemphigoid

Stephanie Goletz¹, Christian Probst², Lars Komorowski², Christiane Radzimski²,
Swantje Mindorf², Maike M. Holtsche^{1,3}, Manuela Pigors¹, Nina van Beek^{1,3},
Wolfgang Schlumberger², Enno Schmidt^{1,3}

¹Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany, ²Institute of Experimental Immunology, EUROIMMUN AG, Lübeck, Germany, Lübeck, Germany, ³Department of Dermatology, University of Lübeck, Lübeck, Germany, Lübeck, Germany

PO 12. | PAPER NUMBER: 20

PAPER WITHDRAWN

PO 13. | PAPER NUMBER: 24

Tralokinumab as a novel effective therapy for bullous pemphigoid

Roberto Maglie, Maria Efenesia Baffa, Dr Stefano Senatore, Dr Carlo Pipitò, Dr Jole Serra,
Prof Emiliano Antiga
University of Florence, Florence, Italy

PO 14. | PAPER NUMBER: 25

Association of FOXP3 gene variant rs3761548 with pemphigus vulgaris: a pilot study

Charoula Achilla^{1,2}, Parthena Meltzanidou^{2,3}, Alexandros Lambropoulos^{1,2,4}, Aikaterini Patsatsi^{2,3},
Anthi Chatzikyriakidou^{2,4}

¹Laboratory of Medical Biology-Genetics, Medical School, Aristotle University, Thessaloniki,, Greece, ²Greek Center of Expertise on AIBD, Papageorgiou General Hospital, Medical School, Aristotle University, Thessaloniki,, Greece, ³2nd Department of Dermatology, Papageorgiou General Hospital, Medical School, Aristotle University, Thessaloniki,, Greece, ⁴Genetic Unit, 1st Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, Medical School, Aristotle University, Thessaloniki, Greece

PO 15. | PAPER NUMBER: 28

Safety, tolerability, and pharmacokinetics of TPM203, a tolerizing Topas particle mixture in pemphigus vulgaris: preliminary results from a phase 1, first in man study (EudraCT Number: 2019-001727-12)

Dario Didona¹, Karolin Volkmann¹, Julia Hinterseher¹, Christian Möbs¹, Alexandra Polakova¹, Sabine Fleischer², Michael Hertl¹

¹Philipps-Universität Marburg, Marburg, Germany, ²Topas Therapeutics GmbH, Hamburg, Germany

PO 16. | PAPER NUMBER: 30

A Case of Psoriasis and Pemphigus Foliaceous in a 55-year-old Filipino

Anikka Mae Crystal Ollet, Ma. Desiree Hannah Garcia, Clarisse Mendoza
Research Institute for Tropical Medicine, Muntinlupa, Philippines

e-POSTERS

PO 17. | PAPER NUMBER: 31

Bullous pemphigoid in a patient with psoriasis and acquired reactive perforating collagenosis

Virginia Evdokia Pappa, Stella Arampatzi, Theodoros Sidiropoulos

State Dermatology Department, Hospital of Venereal and Skin Diseases of Thessaloniki, Thessaloniki, Greece

PO 18. | PAPER NUMBER: 33

Oral Mucosal Telangiectasias as the only clinical sign of a pre-clinical Crest Syndrome case

Efthymia Karagiannopoulou¹, Panagiotis Marinos², Athina Theodoridou³, Dimitrios Andreadis⁴

¹Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University, Thessaloniki, Greece, ²DDS, Thessaloniki, Greece, ³MD,MSc,PhD, Rheumatologist, Thessaloniki, Greece,

⁴Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University, Thessaloniki, Greece

PO 19. | PAPER NUMBER: 34

Gender and Race/Ethnicity in Autoimmune Blistering Diseases: Do Women and Racial/Ethnic Minorities Experience a Disproportionate Burden of Disease?

Marney White¹, Marc Yale², Rebecca Strong², Mary Tomayko¹

¹Yale School of Public Health; Yale School of Medicine, New Haven, United States, ²International Pemphigus & Pemphigoid Foundation, Roseville, United States

PO 20. | PAPER NUMBER: 38

The improved keratinocyte dissociation assay using desmoglein-knockout keratinocytes

Masahiro Tsutsumi, Hiroshi Koga, Kwesi Teye, Norito Ishii, Takekuni Nakama

Department of Dermatology, Kurume University School of Medicine, Kurume-shi, Japan

PO 21. | PAPER NUMBER: 39

Efficacy and safety of different rituximab dosage regimens in pemphigus patients: A multicenter retrospective study

Qijun Wang^{1,7}, Panpan Shang^{2,7}, Yiu Nam^{3,7}, Xingli Zhou^{4,7}, Hanmei Zhang^{5,7}, Ruixin Li^{6,7}, Baoqi Yang^{6,7}, Suying Feng^{5,7}, Wei Li^{4,7}, Jieyue Liao^{3,7}, Guiying Zhang^{3,7}, Mingyue Wang^{2,7}, Xixue Cheng^{2,7}, Jie Zheng^{1,7}, Meng Pan^{1,7}, Xuejun Zhu^{1,7}

¹Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Department of Dermatology, Peking University First Hospital, Beijing, China,

³Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, China, ⁴Department of Dermatology & Venereology, Rare Diseases Center, West China Hospital,

Sichuan University, Chengdu, China, ⁵Department of Dermatology, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ⁶Department of

Dermatology, Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical

Sciences, Jinan, China, ⁷National Autoimmune Bullous Disease Cooperative Group, China

PO 22. | PAPER NUMBER: 41

Laminin β 4 as autoantigen of anti-p200 pemphigoid: pathogenicity and potential interaction with laminin α 3 and γ 2

Manuela Pigors¹, Stephanie Goletz¹, Yao Wang², Shirin Emtenani¹, Christoph M. Hammers¹,

Maike M. Holtsche¹, Sabrina Patzelt¹, Bianca Opelka¹, Felix H. Stang³, Inke R. Koenig¹,

Christiane Radzinski⁴, Lars Komorowski⁴, Monique Aumailley⁵, Cristina Has², Enno Schmidt¹

¹University of Luebeck, Luebeck, Germany, ²Medical Center, University of Freiburg, Freiburg, Germany, ³University Hospital Schleswig-Holstein, Luebeck, Germany, ⁴EUROIMMUN AG, Luebeck,

Germany, ⁵University of Cologne, Cologne, Germany

e-POSTERS

PO 23. | PAPER NUMBER: 42

Topical C5aR1 inhibition reduced clinical lesions in a preclinical model of mucous membrane pemphigoid

Sabrina Patzelt¹, Manuela Pigors¹, Stanislav Khil'chenko¹, Shirin Emtenani¹, Mayumi Kamaguchi¹, Lenche Chakievska¹, Katja Bieber¹, Pasquale Cocchiario², Laura Brandolini², Andrea Aramini², Marcello Allegretti², Ralf Ludwig¹, Enno Schmidt^{1,3}

¹Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany, ²Dompé Farmaceutici SpA, L'Aquila, Italy, ³Department of Dermatology, Allergology and Venerology, University of Lübeck, Lübeck, Germany

PO 24. | PAPER NUMBER: 43

A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis

Eleni Paschou¹, Ilias Papadimitriou¹, Aikaterini Tsentemeidou¹, Dimitra Kiritsi¹, Stamatios Gregoriou², Aimilios Lallas¹, Elena Sotiriou¹, Efstratios Vakirlis¹

¹First Department of Dermatology and Venereology, School of Medicine, Aristotle University, Thessaloniki, Greece, ²1st Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece

PO 25. | PAPER NUMBER: 44

Development of bullous pemphigoid during treatment with benralizumab for eosinophilic asthma

Chrysostomos Goulas¹, Christos Moulas¹, Konstantina Mavridou¹, Evangelia Lampri², Georgios Gaitanis^{3,4}

¹Dermatology Clinic, University Hospital of Ioannina, Ioannina, Greece, ²Laboratory of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece, ³Department of Skin and Venereal Diseases, Faculty of medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece, ⁴DELC Clinic, Biel/Bienne, Switzerland

PO 26 | PAPER NUMBER: 48

Retrospective Analysis of Clinical and Immunoserological Features of Anti-p200 Pemphigoid in a Chinese National Medical Center

Suo Li, **Hanmei Zhang**, **Suying Feng**

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China

PO 27 | PAPER NUMBER: 49

Effective treatment of Bullous Pemphigoid in a patient with nephrotic syndrome with Mycophanolate Mofetil (Case Presentation)

Elli Kampra, Emmanouil Karampinis, Olga Kouvarou, Kleoniki Chaidaki, Polyxeni Gidarokosta, Angeliki Viktoria Roussaki Schulze, **Efterpi Zafiriou**

Department of Dermatology, University Hospital of Larissa, University of Thessaly, Larissa, Greece

PO 28 | PAPER NUMBER: 50

Comedonic pemphigus erythematosus: does it exist?

Kossara Drenovska, Grisha Mateev, Martin Shahid, Snežina Vassileva

Department of Dermatology and Venereology, Medical University-Sofia, Sofia, Bulgaria

PO 29. | PAPER NUMBER: 51

Hard as a rock: a case of massive rupioid psoriasis

Dario Didona¹, Biagio Didona²

¹Philipps-Universität Marburg, Marburg, Germany, ²Istituto Dermatologico dell'Immacolata, IDI-IRCCS, Rome, Italy

e-POSTERS

PO 30. | PAPER NUMBER: 53

The use of dipeptidyl peptidase-4 inhibitors modifies the interplay between the cutaneous cytokines, eosinophils and epitope spectra of anti-BP180 IgG autoantibodies in bullous pemphigoid
Nina Kokkonen^{1,2}, Jussi Tuusa^{1,2}, Outi Lindgren^{2,3,4}, Laura Huilaja^{1,2,4}, Outi Varpuluoma^{1,2,4}, Kaisa Tasanen^{1,2,4}

¹University of Oulu, Department of Dermatology, Oulu, Finland, ²Medical Research Center Oulu, Oulu, Finland, ³University of Oulu, Department of Pathology, Oulu, Finland, ⁴Oulu University Hospital, Oulu, Finland

PO 31. | PAPER NUMBER: 54

Topical Baricitinib in Alopecia Areata: A Case Report

Eleftheria-Loukritia Dikopoulou², Kleoniki Chaidaki¹, Olga Kouvarou¹, Efterpi Zafiriou¹

¹Dermatology Department, General University Hospital, Larissa, Greece, ²University of Thessaly, Medical school, Larissa, Greece

PO 32. PAPER NUMBER: 55

Facilitation of diagnosis of pemphigoid diseases with serum autoantibodies against the dermal side of salt-split skin by indirect immunofluorescence microscopy

Sabrina Patzelt¹, Charlotte Kiehne^{1,2}, Kossara Drenovska³, Christian Probst⁴, Lars Komorowski⁴, Swantje Mindorf⁴, Enno Schmidt^{1,2}, Stephanie Goletz¹

¹Lübeck Institute of Experimental Dermatology, Lübeck, Germany, ²Department of Dermatology Lübeck, Lübeck, Germany, ³Department of Dermatology and Venereology, Medical University, Sofia, Bulgaria, ⁴Institute of Experimental Immunology, EUROIMMUN AG, Lübeck, Germany

PO 33. | PAPER NUMBER: 58

Navigating the Complexities of Rupoid Psoriasis: A Successful Treatment Journey

Ma. Bernadette Sedano, Marion Odette Alonzo
Southern Isabela Medical Center, Philippines

PO 34. | PAPER NUMBER: 59

Correlation between mucous membrane pemphigoid and malignant transformation in the oral mucosa

Effimia Stergiadou¹, Dimitrios Andreadis¹, Aikaterini Patsatsi², Athanasios Pouloupoulos¹

¹Department of Oral Medicine and Pathology, School of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Second Clinic of Dermatology and Venereology, School of Medicine, "G. Papageorgiou" Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

PO 35. | PAPER NUMBER: 60

HLA-DQB1 typing among Bulgarian patients with dermatitis herpetiformis

Martin Shahid¹, **Kossara Drenovska**¹, Milena Ivanova², Elisaveta Naumova², Snejina Vassileva¹

¹Department of Dermatology and Venereology, Medical University - Sofia, Bulgaria, ²Department of Clinical Immunology, Medical University - Sofia, Bulgaria

PO 36. | PAPER NUMBER: 61

PAPER WITHDRAWN

PO 37. | PAPER NUMBER: 62

Charting New Territory: Chronic Bullous Disease of Childhood in Adolescence

Ma. Bernadette Sedano, Karel Helden Dator, Jolene Kristine Dumlaog
Southern Isabela Medical Center, Santiago City, Philippines

e-POSTERS

PO 38. | PAPER NUMBER: 63

Immune checkpoint inhibitor induced peristomal localized bullous pemphigoid

Nikoletta Tsavalopoulou, Eleni Stroumpi, Vasiliki Nikolaou, Maria Politou, Alexandros Stratigos
Andreas Sygros Hospital of Venereal & Dermatological Diseases, Athens, Greece

PO 39. | PAPER NUMBER: 64

A case of diffuse Cutaneous Bullous Mastocytosis in an 8-month-old female seen at Southern Isabela Medical Center

Ayrton Michael Gonzales, Mark Gerald Serrano, Cybill Uy, Jolene Dumlao
Southern Isabela Medical Center, Santiago City, Philippines

PO 40. | PAPER NUMBER: 65

Drug- induced bullous pemphigoid in a patient with treatment resistant psoriasis successfully treated with Ustekinumab (case report)

Kleoniki Chaidaki, Olga Kouvarou, Elli Kampra, Polyxeni Gidarokosta, Agoritsa Gravani, Angeliki Viktoria Roussaki Schulze, **Efterpi Zafiriou**
Department of Dermatology, University Hospital of Larissa, University of Thessaly, Larissa, Greece

PO 41. | PAPER NUMBER: 66

Localized form of oral lichen planus (OLP) in of the upper lip and gingiva. A new subtype?

Panagiotis Marinos, Eleytherios Anagnostou, Dimitrios Andreadis
Dentist, Greece

PO 42. | PAPER NUMBER: 71

When trichoscopy is not enough: a single-center study of clinical and trichoscopic characteristics of hair disorders demanding histopathologic confirmation of the diagnosis.

Anna Vatalachou, Eirini Kyrmanidou, Maria Mpoziou, Elisavet Lazaridou, Zoi Apalla
Second Department of Dermatology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

PO 43. | PAPER NUMBER: 72

The Patient's Perspective: Evaluation of Bullous Pemphigoid Information on Social Media Platforms

Ezdean Alkurdi¹, Dany Alkurdi³, Robert Li¹, Omar Alani³, Prem Patel¹, Zachary Schwager²
¹University of Massachusetts Chan School of Medicine, Worcester, United States, ²Lahey Hospital and Medical Center, Burlington, USA, ³Icahn School of Medicine at Mount Sinai, New York City, USA

PO 44. | PAPER NUMBER: 73

Mucous membrane pemphigoid associated with malignancy

Elia Valeva, Kosara Drenovska, Martin Shahid, Snejina Vassileva
Department of Dermatology and Venereology, Medical University - Sofia, Sofia, Bulgaria

PO 45. | PAPER NUMBER: 74

The Hair Diseases Outpatient Clinic of Papageorgiou Hospital: an epidemiologic study

Eirini Kyrmanidou, Anna Vatalachou, Maria Mpoziou, Zoi Apalla, Elizabeth Lazaridou
Aristotle University of Thessaloniki, Greece

e-POSTERS

PO 46. | PAPER NUMBER: 75

Mucous membrane pemphigoid diagnostics with western blot analysis

Tereza Olejková¹, **Lucia Vojtěchová**², Zuzana Hayek¹, Hana Jedli ková², Iva Slaninová¹

¹Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic,

²Department of Dermatovenereology, St. Anna University Hospital, Masaryk University, Brno, Czech Republic

PO 47. | PAPER NUMBER: 76

Refractory and life threatening pemphigus vulgaris in an elderly female patient

Eleni Stroumpi, Nikoleta Tsavalopoulou, Aristeidis Vaiopoulos, Maria Politou,

Panagiotis Kotitsas, Eirini Stefanaki, Marina Papoutsaki, Alexandros Stratigos

Andreas Sygros Hospital of Venereal and Dermatological Diseases, Athens, Greece

PO 48. | PAPER NUMBER: 78

Epitope-dependent autoantibody-mediated skin inflammation in pemphigoid

Bianca Opelka¹, Kathrin Kalies², Stephanie Goletz¹, Enno Schmidt^{1,3}

¹Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany, ²Institute for Anatomy, University of Lübeck, Lübeck, Germany, ³Department of Dermatology, University of Lübeck, Lübeck, Germany

PO 49. | PAPER NUMBER: 79

Antirituximab antibodies - do they play any role in the treatment response and course of pemphigus?

Anastasia Tsitlakidou¹, Parthena Meltzanidou¹, A. Giannakou², A. Fleva², M. Bantadaki²,

A. Daponte¹, Anna Vatalachou¹, Ms Sofia-Andriani Theodorelou-Charitou¹, E. Kalloniati¹,

A. Tsaousi¹, D. Andreadis³, Elisabeth Lazaridou¹, Aikaterini Patsatsi¹

¹Center of Expertise on Autoimmune Bullous Diseases, ²nd Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece, ²Department of Immunology-Histocompatibility, Papageorgiou General Hospital, Thessaloniki, Greece, ³Department of Oral Medicine

PO 50. | PAPER NUMBER: 80

Nail involvement in pemphigus: a prospective clinical and dermoscopic study

Anissa Zaouak, Amal Chamli, Houda Hammami, Samy Fenniche

Dermatology Department, Habib Thameur Hospital, Tunis, Tunisia

PO 51. | PAPER NUMBER: 81

Case of a patient with Pemphigus Vulgaris treated with Rituximab with special course during the covid-19 era

Argyroula Papadopoulou, Panagiotis G. Stavropoulos

Dermatologist, Athens, Greece

PO 52. | PAPER NUMBER: 82

Demographic data and decision-making processes in patients with Bullous Pemphigoid receiving dupilumab treatment

Efthymia Soura¹, Maria Gerochristou², Theodora Douvali², Maria Kanakari², Argyro Anna

Karamparmpa², Vasiliki Papadopoulou³, Anastasia Tsitlakidou³, Elisavet Lazaridou³, Aikaterini

Patsatsi³, Chrysa Oikonomou⁴, Katerina Grafanaki⁴, Sofia Georgiou⁴, Maria Polina Konstantinou⁵,

Aikaterini Chatziperrou⁵, Konstantinos Krasagakis⁵, Dimitra Kiritsi⁶, Nikolaos Chaitidis⁶,

Konstantinos Giagkidis⁶, Afroditi Noti⁶, Efstratios Vakirlis⁶, Elena Sotiriou⁶, Alexander Stratigos¹,

Vassiliki Chasapi², for the Greek Study Group of Autoimmune Bullous Diseases

¹st University department of Dermatology Venereology Andreas Sygros Hospital, National Kapodistrian university of Athens, ²State Clinic of Dermatology Venereology Andreas Sygros Hospital, ³Center of Expertise on Autoimmune Bullous Diseases, ²nd Dermatology Department, Aristotle University School of Medicine, Papageorgiou Hospital, Thessaloniki, Greece, ⁴Dermatology Department, University of Patra, ⁵Department of Dermatology, University General Hospital of Heraklion, Crete, Greece, ⁶st Department of Dermatology, Aristotle University of Thessaloniki, Thessaloniki, Greece

e-POSTERS

PO 53. | PAPER NUMBER: 83

Clinical and Epidemiological Characteristics of Gliptin-Induced Bullous Pemphigoid: The Greek Experience

Dimitra Kiritsi^{1,2}, Sophia Georgiou³, Alexandros Katoulis⁴, Konstantinos Krasagakos⁵, Maria-Polina Konstantinou⁵, Theodoros Sidiropoulos⁶, Agoritsa Gravani⁷, Aikaterini Grafanaki³, Chrysoula Oikonomou⁷, Kleoniki Chaidaki⁷, Konstantinos Theodoropoulos⁴, Eftichia Kitsiou⁴, Chrysanthi Manou⁴, Nikolaos Chaitidis¹, Konstantinos Giagkidis⁸, Afroditi Noti⁸, Aikaterini Chatziperrou⁵, Parthena Meltzanidou⁹, Athena Ioanna Daponte⁹, Evangelia Kalloniati⁹, Anastasia Tsitlakidou⁹, Athanasia Tsaousi⁹, Efstratios Vakirlis¹, Elisavet Lazaridou⁹, Elena Sotiriou¹, Aikaterini Patsatsi⁸

¹First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Department of Dermatology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ³Dermatology Department, University of Patra, Patra, Greece, ⁴Second Dermatology Department, Attiko Hospital, Athens, Greece, ⁵Dermatology Department, University General Hospital of Heraklion, Crete, ⁶State Dermatology Department, Skin and Venereal Diseases Hospital, Thessaloniki, Greece, ⁷Dermatology Department, School of Medicine, University of Thessaly, Larisa, Greece, ⁸School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁹Second Dermatology Department, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece, for the Greek Study Group of Autoimmune Bullous Diseases

PO 54. | PAPER NUMBER: 84

Epidemiology of Pemphigus in Greece: A 5-year, multicenter Study

Maria Polina Konstantinou^{1,13}, Konstantinos Krasagakos^{1,13}, Aikaterini Chatziperrou^{1,13}, Efrosyni Markaki^{1,12,13}, Maria Emmanouela Anagnostaki^{2,13}, Aikaterini Kyriakou^{2,13}, Anastasia Tsitlakidou^{2,13}, Elisavet Lazaridou^{2,13}, Eutuxia Kitsiou^{3,13}, Chrysanthi Mamou^{3,13}, Konstantinos Theodoropoulos^{3,13}, Alexandros Katoulis^{3,13}, Theodoros Sidiropoulos^{4,13}, Agoritsa Gravani^{5,13}, Angeliki-Viktoria Roussaki-Schulze^{5,13}, Chrysa Oikonomou^{6,13}, Katerina Grafanaki^{6,13}, Sophia Georgiou^{6,13}, Panagiota Tanga^{7,13}, Markos Papakonstantis^{7,13}, Dimitra Kiritsi^{8,13}, Efstratios Vakirlis^{8,13}, Nikolaos Chaitidis^{8,13}, Konstantinos Giagkidis^{8,13}, Afroditi Noti^{8,13}, Efthymia Soura^{9,13}, Alexandros Stratigos^{9,13}, Maria Gerochristou^{10,13}, Theodora Douvali^{10,13}, Vassiliki Chassapi^{10,13}, Georgios Gaitanis^{11,13}, Aikaterini Patsatsi^{2,13}

¹Dermatology Department, University General Hospital of Heraklion, Crete, Heraklion, Greece, ²Autoimmune Bullous Diseases Unit Greek Center of Expertise on AIBD, ^{2nd} Dermatology Department Aristotle University School of Medicine Papageorgiou General Hospital, Thessaloniki, Greece, ³Second Dermatology Department, Attiko Hospital, Athens, Greece, ⁴State Dermatology Department, Skin and Venereal Diseases Hospital, Thessaloniki, Greece, ⁵Dermatology Department, University of Thessaly, Larissa, Greece, ⁶Dermatology Department, University of Patras, Patra, Greece, ⁷Dermatology Department, 401 General Military Hospital of Athens, Athens, Greece, ⁸First Dermatology Department, Skin and Venereal Diseases Hospital, Thessaloniki, Greece, ⁹1st University department of Dermatology Venereology Andreas Sygros Hospital, National Kapodistrian university of Athens, Athens, Greece, ¹⁰State Dermatology Department, A. Sygros Hospital, Athens, Greece, ¹¹Dermatology Department, University of Ioannina, Ioannina, Greece, ¹²Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School, University of Crete, Heraklion, Greece, ¹³for the Greek Study Group of Autoimmune Bullous Diseases

PO 55. | PAPER NUMBER: 85

Advantages of rituximab therapy early in the course of pemphigus - data from northern Greece

Anastasia Tsitlakidou¹, A. Daponte¹, E. Kalloniati¹, A. Tsaousi¹, V. Ofliidou¹, D. Andreadis², Elisabeth Lazaridou¹, Aikaterini Patsatsi¹

¹Center of Expertise on Autoimmune Bullous Diseases, ^{2nd} Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece, ²Department of Oral Medicine

e-POSTERS

PO 56. | PAPER NUMBER: 86

Castleman Disease after a 10-year period of Bullous Disease: Pemphigus Vulgaris or Paraneoplastic Pemphigus in disguise?

Sotiria Stefaniotou, Georgia Pappa, Konstantinos Theodoropoulos, Sofia Theotokoglou, Anna Syrmali, Dimitrios Sgouros, Panagiota Loumou, Eirini Galiatsou, Alexander Katoulis
2nd Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece

PO. 57 | PAPER NUMBER: 87

Bullous pemphigoid in Greece: Epidemiological evidence and impact of diabetes mellitus and gliptin use on adjuvant treatment administration - a five-year study

Agoritsa Gravani^{1,8}, Katerina Grafanaki^{3,8}, Kleoniki Chaidaki^{1,8}, Angeliki-Viktoria Roussaki-Schulze^{1,8}, Athina Ioanna Daponte^{2,8}, Evangelia Kalloniati^{2,8}, Sofia-Andriani Theodorelou-Charitou^{2,8}, Anastasia Tsitlakidou^{2,8}, Elisavet Lazaridou^{2,8}, Aikaterini Patsatsi^{2,8}, Chrysa Oikonomou^{3,8}, Sofia Georgiou^{3,8}, Maria Polina Konstantinou^{4,8}, Aikaterini Chatziperrou^{4,8}, Konstantinos Krasagakis^{4,8}, Eutuxia Kitsiou^{5,8}, Chrysanthi Mamou^{5,8}, Konstantinos Theodoropoulos^{5,8}, Alexandros Katoulis^{5,8}, Theodoros Sidiropoulos^{6,8}, Dimitra Kiritsi^{7,8}, Elena Sotiriou^{7,8}

¹Dermatology Department, University Hospital of Larissa, Greece, Larissa, Greece, ²Second Dermatology Department, Papageorgiou Hospital, Thessaloniki, ³Department of Dermatology, University Hospital of Patras, School of Medicine, University of Patras, Patras, Greece, ⁴Dermatology Department, University General Hospital of Heraklion, Crete, ⁵Second Dermatology Department, Attiko Hospital, Athens, Greece, ⁶State Dermatology Department, Skin and Venereal Diseases Hospital, Thessaloniki, ⁷First Dermatology Department, Skin and Venereal Diseases Hospital, Thessaloniki, ⁸On behalf of the Greek Bullous Diseases study group

PO 58. | PAPER NUMBER: 90

Erythrodermic psoriasis: Complete remission after administration of Bimekizumab

Vasiliki Papadopoulou, Aikaterini Patsatsi, Zoi Apalla, Evangelia Kalloniati, Myrto-Georgia Trakatelli, Christina Fotiadou, Aikaterini Kyriakou, Elisavet Lazaridou
2nd Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki

PO 59. | PAPER NUMBER: 91

Association of Serum Levels of Total-IgE Autoantibodies With Disease Activity and Severity in Patients with Bullous Pemphigoid

Aikaterini Kyriakou¹, Parthena Meltzanidou¹, Sofia - Andriani Theodorelou - Charitou¹, Efimia Zagliverinou¹, Valentina Oflidou¹, Alexandra Fleva², Maria Bantadaki², Anastasia Giannakou², Elisavet Lazaridou¹, Aikaterini Patsatsi¹

¹Center of Expertise on AIBD, ²2nd Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece, ²Center of Expertise on AIBD, Department of Immunology - Histocompatibility, Papageorgiou General Hospital, Thessaloniki, Greece

PO 60. | PAPER NUMBER: 92

Epidermolysis Bullosa Acquisita in a 2-Year-Old Girl: A Case Report

Paulina Barasińska, Dorota Sobolewska-Sztychny, Joanna Narbutt, **Aleksandra Lesiak**
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Laboratory of Autoinflammatory, Genetic and rare Skin Disorders Medical University of Lodz, Lodz, Poland

GENERAL INFORMATION

CONFERENCE VENUE

HOTEL MAKEDONIA PALACE
2. M. Alexandrou Av.
546 40, Thessaloniki, Greece
T: +30 231 089 7197
E: info@makedoniapalace.gr
W: www.makedoniapalace.com

REGISTRATION SECRETARIAT

OPENING HOURS

The Registration Secretariat will be situated at the Conference Venue and will be operating according to the following schedule:

THURSDAY 29|8|2024 08:00 - 18:00

FRIDAY 30|8|2024 08:00 - 18:00

SATURDAY 31|8|2024 08:00 - 17:00

COFFEE BREAKS & LIGHT LUNCHES

Coffee breaks & light lunches will be offered to all registered participants, according to the time schedule announced in the Scientific Program.

EXHIBITION HALL

The Exhibition will be organized at the Conference Venue.

LANGUAGE

Official language of the Conference is English. The Greek Session on Saturday will be in Greek and the .pptx presentations will be in English

CONFERENCE BADGES

It is essential that all participants wear their personal badge at all times in the Conference area, as it is the official entrance pass to scientific sessions.

The badge is also mandatory for the Welcome Cocktail to be held on Thursday, August 29th following the Opening Ceremony and the Opening Lectures.

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be sent to all registered participants, after the end of the Conference, via email

SCIENTIFIC PRESENTATIONS AND SPEAKERS' PRESENTATIONS RECEPTION DESK

The Conference Hall offers full audio-visual equipment. A Speakers' Presentation Reception desk will be available at the Conference area. All presentations should be clearly labeled with the author's name and session's title. All speakers are kindly requested to deliver their presentations at least 2 hours prior to the session they participate.

E-POSTERS

e-Posters will be available for viewing during the whole Meeting.

SOCIAL PROGRAM

- **Welcome Reception** on Thursday August 29th at Makedonia Palace Hotel.
- **Networking Event** on Friday August 30th at Shark Restaurant.

INSURANCE & LIABILITY

The Organizers accept no liability for any personal injury, loss or damage of property or additional expenses incurred to conference participants either during the conference or as result of delays, strikes or any other circumstances. Participants are requested to make their own arrangements with respect to health and travel insurance.

PROFESSIONAL CONGRESS ORGANIZER



ERA Ltd
17, Asklipiou str., 106 80 Athens, Greece
T: +30 210 363 4944
E: info@era.gr
W: www.era.gr

Epidermolysis Bullosa (EB)

Estimated
500,000
sufferers worldwide
many of whom are
children

Genetic, Rare and Debilitating Impact on QoL

- It is a rare and incurable disease, characterized by skin fragility and blistering that can lead to painful wounds, scarring, infections, and functional impairment.
- It has a genetic origin and comprises of a number of subtypes that vary in clinical presentation as well as in incidence and prevalence.
- The slightest wound can lead to ulcers and blisters on the skin and mucous membranes.



97 Ymittou street, Athens
t. +30 2107517608, e. info@sfrd.gr
www.sfrd.gr

References:


Tabor A, Pergolizzi JV, Marti G, et al. Raising awareness among healthcare providers about Epidermolysis Bullosa and advancing toward a cure. *J Clin Aesthet Dermatol* 2017; 10(5): 36-48.

Code: C-EB/GR/01-2024



▼ CIBINQO® (abrocitinib) tablets

50mg
100mg
200mg



▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιοσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.



Pfizer Ελλάς Α.Ε.,
Λ. Μεσογείων 243, Ν. Ψυχικό 15451, Αθήνα, Ελλάδα,
Τηλ. Επικοινωνίας 210-6785800,
Αριθ. Γ.Ε.ΜΗ. 000242901000
Pfizer Ελλάς ΑΕ (Cyprus Branch)
Λεωφόρος Αθαλάσσης 26, 2018 Λευκωσία, Κύπρος,
Τηλ.: 22817690

Για πλήρεις συνταγογραφικές πληροφορίες συμβουλευτείτε την Περίληψη Χαρακτηριστικών των Προϊόντων που διατίθενται από την εταιρεία.

**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**

ANTHELIOS UVMUNE 400 spf 50+

ΜΕ ΤΟ ΑΝΤΗΛΙΑΚΟ ΦΙΛΤΡΟ: **MEXORYL 400**

ΤΟ ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΕΡΟ
ΦΙΛΤΡΟ ΕΝΑΝΤΙΑ
ΣΤΙΣ ΠΙΟ ΕΠΙΒΛΑΒΕΙΣ
ΑΚΤΙΝΕΣ UV.

ΓΙΑ ΚΑΘΕ ΤΥΠΟ
ΔΕΡΜΑΤΟΣ



Skyrizi[®]
(risankizumab)

RINVOQ[®] ▽
upadacitinib



Για την ΠΧΠ SKYRIZI[®]
σαρώστε εδώ



Για την ΠΧΠ RINVOQ[®]
σαρώστε εδώ

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

SKYRIZI[®] Τρόπος διάθεσης: Περιορισμένη ιατρική συνταγή από ειδικό ιατρό λόγω ανάγκης καθοδήγησης και επίβλεψης των πρώτων χορηγήσεων και παρακολούθησης κατά τη διάρκεια της αγωγής.
Λιανικές Τιμές: • SKYRIZI INJ.SOL 150MG/ML BTx1 PF.PEN 2790,59 € • SKYRIZI INJ.SOL 150MG/ML BTx1 PF.SYRS 2790,85 €

RINVOQ[®] Τρόπος διάθεσης: Περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.
Λιανικές Τιμές: • RINVOQ PR.TAB 15 MG/TAB, BTx28 775,72 € • RINVOQ PR.TAB 30 MG/TAB, BTx28 1470,46 €

Για περισσότερες πληροφορίες απευθυνθείτε στην εταιρεία:
AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
Μαρίνου Αντύπα 41-45, Νέο Ηράκλειο, 14121, Ελλάδα, Τηλ.: +30 214 4165555

GR-RNQD-240009/02-2024

abbvie

ΣΥΜΒΑΛΛΕΤΕ ΣΤΗΝ ΠΡΟΣΤΑΣΙΑ ΕΝΑΝΤΙ ΤΟΥ ΕΡΠΗΤΑ ΖΩΣΤΗΡΑ ΜΕ ΤΟ SHINGRIX¹

ΤΟ SHINGRIX ΣΥΣΤΗΝΕΤΑΙ ΚΑΙ ΑΠΟΖΗΜΙΩΝΕΤΑΙ
ΓΙΑ ΟΛΟΥΣ ΤΟΥΣ ΕΝΗΛΙΚΕΣ ΗΛΙΚΙΑΣ ≥ 60 ΕΤΩΝ ΚΑΙ
ΓΙΑ ΑΝΟΣΟΚΑΤΕΣΤΑΛΜΕΝΑ ΑΤΟΜΑ ΗΛΙΚΙΑΣ ≥ 18 ΕΤΩΝ²

Σύνοψη προφίλ ασφάλειας: Το SHINGRIX αντενδείκνυται σε οποιονδήποτε έχει υπερευαίσθη-
σία στις δραστικές ουσίες ή σε κάποιο από τα έκδοχα. Όπως συμβαίνει με όλα τα ενέσιμα εμβόλια, η
κατάλληλη ιατρική θεραπεία και επίβλεψη θα πρέπει να είναι πάντα άμεσα διαθέσιμη σε περίπτωση
αναφυλακτικού συμβάντος μετά τη χορήγηση του εμβολίου.

Σε ενήλικες ηλικίας 50 ετών και άνω οι πιο συχνά αναφερόμενες ανεπιθύμητες ενέργειες ήταν άλγος
στη θέση ένεσης (68,1% συνολικά/δόση, 3,8% σοβαρού βαθμού/δόση), μυαλγία (32,9% συνολικά/
δόση, 2,9% σοβαρού βαθμού/δόση), κόπωση (32,2% συνολικά/δόση, 3,0 % σοβαρού βαθμού/
δόση) και κεφαλαλγία (26,3% συνολικά/δόση, 1,9% σοβαρού βαθμού/δόση). Οι περισσότερες από
αυτές τις ανεπιθύμητες ενέργειες δεν ήταν μεγάλης διάρκειας (διάμεση διάρκεια 2 έως 3 ημέρες). Η
διάρκεια των ανεπιθύμητων ενεργειών που αναφέρθηκαν ως σοβαρές ήταν 1 έως 2 ημέρες. Σε ενή-
λικες ηλικίας ≥ 18 ετών που έχουν ανοσοανεπάρκεια ή βρίσκονται σε ανοσοκαταστολή λόγω νόσου
ή θεραπείας (αναφέρονται ως ανοσοκατεσταλμένοι (IC)), το προφίλ ασφάλειας ήταν σε συμφωνία
με εκείνο που παρατηρήθηκε σε ενήλικες ηλικίας 50 ετών και άνω. Υπάρχουν περιορισμένα δεδο-

μένα σε ενήλικες ηλικίας 18-49 ετών με αυξημένο κίνδυνο ΗΖ που δεν είναι IC. Συνολικά, υπήρξε
υψηλότερη συχνότητα εμφάνισης κάποιων ανεπιθύμητων ενεργειών σε νεότερες ηλικιακές ομάδες:

- μελέτες σε IC ενήλικες ηλικίας ≥ 18 ετών (συγκεντρωτική ανάλυση): η συχνότητα εμφάνισης πόνου
στο σημείο της ένεσης, κόπωσης, μυαλγίας, κεφαλαλγίας, ρίγους και πυρετού ήταν υψηλότερη σε
ενήλικες ηλικίας 18-49 ετών σε σύγκριση με αυτούς ηλικίας 50 ετών και άνω.

- μελέτες σε ενήλικες ηλικίας ≥ 50 ετών (συγκεντρωτική ανάλυση): η συχνότητα εμφάνισης μυαλ-
γίας, κόπωσης, κεφαλαλγίας, ρίγους, πυρετού και γαστρεντερικών συμπτωμάτων ήταν υψηλότερη
σε ενήλικες ηλικίας 50-69 ετών σε σύγκριση με αυτούς ηλικίας 70 ετών και άνω.

Δεν υπάρχουν δεδομένα από τη χρήση του SHINGRIX σε έγκυες γυναίκες. Ως προληπτικό μέτρο,
είναι προτιμότερο να αποφεύγεται η χρήση του SHINGRIX κατά τη διάρκεια της εγκυμοσύνης. Εί-
ναι άγνωστο εάν το SHINGRIX απεκκρίνεται στο ανθρώπινο γάλα. Όπως συμβαίνει με οποιοδήποτε
εμβόλιο, ο εμβολιασμός με SHINGRIX μπορεί να μην έχει ως αποτέλεσμα την προστασία όλων των
εμβολιασμένων.

Βιβλιογραφία: 1. SHINGRIX, Περίληψη των Χαρακτηριστικών του Προϊόντος, Οκτώβριος 2023. 2. Εθνικό
Πρόγραμμα Εμβολιασμού Ενηλίκων 2024.

Λ.Τ.: 165,86 €. % επιχορήγησης από τους οργανισμούς κοινωνικών ασφαλίσεων: 100% για τους πληθυσμούς
που περιγράφονται στο Εθνικό Πρόγραμμα Εμβολιασμών Ενηλίκων. Φαρμακευτικό προϊόν για το οποίο απαι-
τείται ιατρική συνταγή. Τα ανωτέρω ισχύουν κατά την ημερομηνία σύνταξης του εντύπου/καταχώρησης.
Παρακαλούμε επικοινωνήστε με την εταιρία για επιβεβαίωση πλήρως ενημερωμένων δεδομένων, για οποια-
δήποτε πληροφορία ή/και αναφορά Ανεπιθύμητων Ενεργειών στο τηλέφωνο 210 6882100.

PM-GR-SGX-ADVT-230002 | 03/2024 - 03/2026



Πριν τη συνταγογράφηση
συμβουλευτείτε την Περί-
ληψη των Χαρακτηριστι-
κών του Προϊόντος. Για την

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή
και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες
για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



Περίληψη των Χαρακτηριστικών του Προϊόντος σκανάρετε το QR code. Σε έντυπη μορφή είναι διαθέσιμη
κατόπιν αιτήσεως στην εταιρία. Το εμπορικό σήμα ανήκει ή έχει παραχωρηθεί στον Όμιλο Εταιρειών GSK.
© 2024 Όμιλος εταιρειών GSK ή δικαιούπαρχος του Ομίλου GSK.

GSK

GlaxoSmithKline ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.Β.Ε.
Λ. Κηφισίας 266, 152 32 Χαλάνδρι, Αθήνα, Τηλ.: 210 6882100
www.gr.gsk.com



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

ΤΩΡΑ ΜΠΟΡΕΙΣ

 **Opzelura®**
ruxolitinib cream

Η πρώτη και η μόνη
εγκεκριμένη θεραπεία
για επαναχρωματισμό
της μη τμηματικής λεύκης^{1,2}

Για την Περίληψη
Χαρακτηριστικών του
προϊόντος σκανάρετε
τον κωδικό QR



Η πιο συχνή ανεπιθύμητη ενέργεια είναι
η ακμή στη θέση εφαρμογής (5,8%).¹

Περαιτέρω πληροφορίες διατίθενται
από τη GENESIS Pharma

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή
και Αναφέρετε:
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Βιβλιογραφία:

1. Opzelura Περίληψη Χαρακτηριστικών του Προϊόντος.
2. Hwang JR, Driscoll MS. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo. *Annals of Pharmacotherapy*. 2023;57(8):948-955. doi:10.1177/10600280221143748.

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ:

Περιορισμένη ιατρική συνταγή από ειδικό ιατρό
και παρακολούθηση κατά τη διάρκεια της αγωγής.

Ενδεικτική τιμή ΟΡΖΕΛΥΡΑ ΚΡΕΜΑ 15ΜΓ/Γ
ΒΤ x 1ΤΥΒΕx100g: 750€

Επί του παρόντος το φαρμακευτικό προϊόν
δεν είναι εμπορικά διαθέσιμο.

 **GENESIS**
pharma

Λ. Κηφισίας 274, 15232 Χαλάνδρι, Αθήνα,
Τηλ.: 210 8771500, Fax: 210 6891918,
e-mail: info@genesishpharma.com,
www.genesishpharma.com

 **Incyte**
Dermatology

AMGEN®

Inflammation

AMGEVITA™
(adalimumab)



Otezla®
(apremilast) 30mg tablets



Τρόπος διάθεσης: Περιορισμένη ιατρική συνταγή. Η διάγνωση και/ή η έναρξη της θεραπείας γίνεται σε νοσοκομείο και μπορεί να συνεχίζεται και εκτός νοσοκομείου υπό την παρακολούθηση ειδικού ιατρού.
AMGEVITA INJ. SOL 40MG/0,8ML BTx2 PEPENS (SureClick) x 0,8ML Λ.Τ.: 601,63€
AMGEVITA INJ. SOL 40MG/0,8ML BTx2 PFSYRS x 0,8ML Λ.Τ.: 601,63€
AMGEVITA INJ. SOL 20MG/0,4ML BTx1 PFSYR x 0,4ML Λ.Τ.: 171,29€

Τρόπος διάθεσης: Περιορισμένη ιατρική συνταγή από ειδικό γιατρό και παρακολούθηση κατά την διάρκεια της αγωγής.
OTEZLA F.C. TAB 30MG/TAB BT x 27 δισκία (4 δισκία x 10MG + 4 δισκία x 20MG + 19 δισκία x 30MG) σε BLISTERS PVC/αλουμίνιο – σε καρτέλα Λ.Τ.: 287,64€
OTEZLA F.C. TAB 30MG/TAB BT x 56 δισκία σε BLISTERS PVC/αλουμίνιο Λ.Τ.: 576,16€

GRC-501-0123-80001

Amgevita SPC



Otezla SPC



Πριν τη συνταγογράφηση συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος, ακανόνοντας το QR code.

AMGEN HELLAS Ε.Π.Ε

Αγ. Κωνσταντίνου 59-61
Κτίριο Γ, Μαρούσι 15 124

Τηλ: 210 3447000 - Fax: 210 3447050
Email: info@amgen.gr, www.amgen.gr

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΜΕΣ τις ανεπιθύμητες ενέργειες για ΟΙΑ τα φάρμακα συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

Αναφέρετε κάθε ύποπτη ανεπιθύμητη ενέργεια σύμφωνα με το εθνικό σύστημα αναφοράς στο Τμήμα Ανεπιθύμητων Ενέργειων του Εθνικού Οργανισμού Φαρμάκων (ΕΟΦ) Τηλ: 2102082000 Fax: 2105490055 με τη χρήση της Κίτρινης Κάρτας. Οδηγίες και στην ιστοσελίδα του ΕΟΦ: www.efpi.gr και επίσης η ηλεκτρονική υποβολή ή ενυπόθηκη στην AMGEN Ελλάς Φαρμακικά Ε.Π.Ε. Τηλ: +30 2103447000.

ACKNOWLEDGEMENTS

PLATINUM SPONSOR



SILVER SPONSORS



BRONZE SPONSORS



SPONSORS




SPONSORS PROFILES



ADVENT is a non-promotional global medical education program by Sanofi and Regeneron, designed to engage healthcare professionals (HCPs) and advance the understanding of the role of type 2 inflammation across several diseases within dermatology, pulmonology, rhinology, and gastroenterology. Offering a wide variety of face-to-face and digital opportunities, the ADVENT program aims to provide HCPs with high-quality, fair-balanced, and continuous education to advance clinical management and improve patient care. At its core, the objectives of the ADVENT program are to educate on type 2 inflammation, with a focus on advancing understanding of pathophysiology and highlighting the significant burden suffered by patients, families, and caregivers. The ADVENT program prioritizes the exploration and dissemination of evolving data on new therapeutic approaches to management and prompts understanding of the multidisciplinary implications and cumulative burden associated with type 2 inflammatory diseases, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid.

The name ADVENT, formed by combining 'AD' (atopic dermatitis & dermatology), 'VENT' (ventilation = pulmonology), and 'ENT' (rhinology), signifies a novel and innovative approach to medical education, which has historically relied on traditional, short-term IME/CME programs. The ADVENT program was designed to disrupt these conventional formats, offering a continuously evolving curriculum of varied digital resources and in-person experiences conducive for diverse learning styles, all of which are developed in collaboration with over 100 global medical experts.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.



SPONSORS PROFILES



Argenx Commitment to Patients

Each day at argenx, we are motivated to pursue a better tomorrow alongside patients. We aim to do this through partnership because we know that “together we are better”. As your ally, we pioneer innovations to advance the understanding of rare diseases; we want to deliver immunology treatments to patients worldwide.

We listen to patients, supporters and advocacy communities; we hear your stories and share your determination. We integrate your aspirations into how we innovate, how we conduct research and design trials, and how we can support you in the daily struggles you face living with a rare disease.

There is a common purpose across argenx that is driven by your resilience and we welcome this opportunity to be with you on this journey.



At UCB, we believe everyone deserves to live the best life that they can – as free as possible from the challenges of disease. We develop solutions across neurology, immunology, and other areas where our expertise, innovation, and ambition align with the needs of those who live with severe diseases.

We are curious and collaborative, driven to create valuable solutions and improve the health and wellbeing of our people, our communities, and the planet. We seek out tools, technologies, and partners that help us respond to patient needs with purposeful innovations that make a truly meaningful impact.

Download the Official IPPF 2024 Mobile App

All information at your fingertips during the Congress

Download the Smartphone App of IPPF2024 meeting by following three simple steps:

1

Download the EventsAir App from Google Play Store or Apple App Store

2

The first time you open the application, you will be prompted for the event code.

Type the code: ippf2024

3

Then to log in, you will need to enter the email and the password that you had used also at the registrations portal/abstract portal

Maximize your conference experience using the smartphone app:

- Access your QR Personal code. Display your code at the registration desk for speedy badge collection.
- Post your messages at the event's social network.
- View from your mobile device the conference Agenda.
- Keep important notes and email them directly to your personal email account.
- Exchange contact details with fellow delegates.



Network: **ippf2024**



IPPF 2024

Bimzelx[®]
(bimekizumab)

ΑΦΗΣΤΕ ΤΗΝ ΨΩΡΙΑΣΗ ΠΙΣΩ ΣΑΣ

ΕΥΚΑΙΡΙΑ ΓΙΑ ΚΑΘΑΡΟ ΔΕΡΜΑ ΓΡΗΓΟΡΑ ΚΑΙ ΜΕ ΔΙΑΡΚΕΙΑ*¹

* Το 85% των ασθενών πέτυχε PASI 90 και 84% IGA 0/1 την εβδομάδα 16. Το 77% πέτυχε PASI 75 την εβδομάδα 4 μετά την πρώτη δόση. Το 59% των ασθενών πέτυχε επίσης PASI 100 την εβδομάδα 16.²

Bimzelx[®]
(bimekizumab)

ΕΥΚΑΙΡΙΑ ΓΙΑ
ΕΞΑΙΡΕΤΙΚΟ ΑΠΟΤΕΛΕΣΜΑ

Με βάση τα δεδομένα για την αποτελεσματικότητα έναντι του εικονικού φαρμάκου, του adalimumab και του ustekinumab σε βασικές μελέτες φάσης III.²⁻⁵

Το BIMZELX[®] (Bimekizumab) ενδείκνυται για τη θεραπεία της μέτριας έως σοβαρής ψωρίασης κατά πλάκας σε ενήλικες που είναι υποψήφιοι για συστηματική θεραπεία.¹

▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει τον γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιοσδήποτε πιθανολογούμενος ανεπιθύμητος ενέργειες.



Για περισσότερες πληροφορίες παρακαλώ καλέστε στο τμήμα UCB Cares.
Δωρεάν κλήση: 0080 012 9910
Τηλεφωνικός αριθμός με χρέωση: 210 99 74 200
Email: UCBcares.GR@ucb.com

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «KITPINH KAPTA»

Βιβλιογραφία: 1. BIMZELX[®] (μπιμεκιζουμάμπη) Περίληψη Χαρακτηριστικών Προϊόντος, Νοέμβριος 2023. https://www.ema.europa.eu/el/documents/product-information/bimzelx-epar-product-information_el.pdf. 2. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475-486. 3. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021;397(10273):487-498. 4. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487-498. Supplementary appendix. 5. Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130-141.

 Inspired by patients.
Driven by science.

Λιανική τιμή (Δ.Τ. 12/2023)

BIMZELX INJ.SOL. 160MG/ML 2 PF. PENS x1 ML: 2379,86 €

BIMZELX INJ.SOL. 160MG/ML 2 PF. SYRS x1 ML: 2379,86 €

GR-BIK-2400023



ADVENT

dermatology



ADVENT is an **award-winning medical education program** developed in collaboration with **over 50 global experts** to advance the understanding of **type 2 inflammation**



Visit
ADVENTprogram.com



Bullous Pemphigoid



Atopic Dermatitis



Prurigo Nodularis



Chronic Spontaneous Urticaria

sanofi | **REGENERON**[®]

ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2404783 - 1.0 - 07/2024